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ABSTRACT
Background: As adults age, there is a progressive decline in cardiovascular and skeletal muscle
function that directly impacts on physical capacity and exercise tolerance. In the elderly, an
increase in energy cost of walking is associated with slower walking speeds and augmented
fatigue. Both cardiovascular function, and in particular heart rate, and physical function such as
walking speed have strong predictability on longevity in this cohort.

Evidence supports that the long chain omega-3 polyunsaturated fatty acid (LC n-3 PUFA),
docosahexaenoic acid (DHA), incorporates into cardiac and skeletal muscle at a dose that is
achievable via fatty fish consumption. In the case of skeletal muscle there is certainly evidence
supporting the improvement of muscular strength at high doses. In fact, population health is
improved by the regular consumption of fatty fish and this is reinforced by direct measures of
physical capacity. In the laboratory, the effect of elevating the omega-3 status of an individual
includes improved heart and skeletal muscle function especially when physiological strain is
increased and supports the need for increased intake of LC n-3 PUFA, especially DHA which is
found in abundance in contractile cells.

Objective: This study sought to determine whether low dose (2g/day), DHA-rich fish oil could
elevate the red blood cell (RBC) omega-3 status and as a result modify heart function and improve
physical capacity in physically active and healthy older adults.

Design: Using randomised placebo-controlled trial, physically fit older adults aged 60-85 years
were supplemented with either 2g/d of DHA-rich fish oil (FO) (delivering 560mg/d DHA and
140mg/d eicosapentaenoic acid (EPA)), or 2g/d of placebo oil (control) (Sunola oil) for 16 weeks.
Omega-3 index (RBC EPA+DHA) was measured before and after supplementation. Participants
i

completed a series of physical function tests, including walking speed over distances of 20-400m.
In addition, a submaximal treadmill ramp protocol was conducted to evaluate the heart rate and
oxygen cost of walking. Most importantly, heart rate was measured during both rest (including
overnight sleep), exercise states and recovery.

Results: In physically fit and healthy older adults (mean walking speed >1.5m/s), the omega-3
index (%) was significantly increased (P<0.01) after fish oil supplementation (n=9) and not
placebo (n=8) (control: pre 6.06±0.29, post 5.88±0.18; FO: pre 6.01±0.23, post 8.31±0.37 %). As
a result, fish oil supplementation significantly lowered heart rate during steady state over ground
walking in the 400m walk test (control: pre 120±2, post 124±2; FO: pre 122±2, post 115±2 bpm,
P<0.01, height as a covariate) with no modification to self-selected walking speed. In addition,
fish oil supplementation also lowered overnight sleeping heart rate (control: -0.2±1.0; fish oil: 3.8±1.2 bpm, P<0.05) without change to the heart rate variability (P>0.05). There was no effect of
increasing the omega-3 index on the oxygen cost of walking (P>0.05) which might help to explain
the non-modification to walking speed (P>0.05) in this already very active group. Additionally,
physical function tasks, including grip strength and timed up and go were not substantially
modified as a result of fish oil supplementation (P>0.05) and may too be due the high physical
function in this group.

Conclusions: This study established that a DHA-rich fish oil dose that is reproducible through
consumption of two fish meals per week significantly improves the omega-3 index (RBC
EPA+DHA) in older adults. This increase in the omega-3 index resulted in improved
cardiovascular function as reflected by the lowering of heart rate, particularity during fast walking.
This study has supported the need to further promote LC n-3 PUFA in the diets of older adults and
highlights this can be achieved via the consumption of regular fish that is rich in DHA.
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1.

Introduction

1.1

Conceptual overview

The course of normal aging results in an alterable reduction in functional capacity of multiple
physiological systems, including cardiovascular and skeletal muscle (Trombetti, Reid et al. 2016,
Jakovljevic 2018). There is a range of physiological factors that influence functional status of the
elderly. These include cardiorespiratory declines that result in a coordinated de-adaptation of
oxygen delivery and utilisation (Daley and Spinks 2000, Burtscher 2013). Throughout adult life,
beginning in approximately the fourth decade (Janssen, Heymsfield et al. 2000), there is a decline
in aerobic capacity and an increase in energy cost of walking which leads to a slower walking
speed which serves to reduce energetic requirements and attenuate fatigue (Wert, Brach et al.
2013). Preferred walking speed slows with age and is a strong predictor of detrimental health
outcomes in older adults (Franklin, Brinks et al. 2015). There is an emerging concept of the
physiological reserve in the elderly which relates to the difference between the maximum physical
or mental capacity and the minimum necessary to perform daily activities, such as walking (Arnett,
Laity et al. 2008, Wert, Brach et al. 2013, Schrack, Zipunnikov et al. 2014). As the physiological
reserve reduces, and energy cost of activity increases, the adaptive process to conserve energy
takes place which collectively results in the onset of fatigue and minimisation of unnecessary
movement (Schrack, Simonsick et al. 2010, González, Cofré et al. 2016).

As it relates to diet, there are many nutritional aspects which enhance functional independence and
longevity, specifically in the elderly (Leslie and Hankey 2015). Proportions of macronutrients in
the diet, quality of fat sources, as well as key nutrients such as calcium, vitamin D and adequate
protein intake have received recognition for their integrative role in protection from coronary heart
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disease (Jakobsen, O'Reilly et al. 2009), muscle mass maintenance (Murphy, Oikawa et al. 2016)
and attenuation of bone mineral density loss (Dawson-Hughes and Harris 2002, Promislow,
Goodman-Gruen et al. 2002, McCabe, Martin et al. 2004).

Notwithstanding the obvious and accepted role of protein to slow the rate of loss of muscle mass
(Murphy, Oikawa et al. 2016), population based research indicates that diets high in
polyunsaturated fatty acids, such as the Mediterranean diet reduce the risk of all-cause and causespecific mortality (Kromhout, Bosschieter et al. 1985, Burr, Fehily et al. 1989, Siscovick,
Raghunathan et al. 1995, Knoops, de Groot et al. 2004), and are associated with a slower decline
in mobility and walking speed over time in the elderly (Abbatecola, Cherubini et al. 2009,
Milaneschi, Bandinelli et al. 2011, Shahar, Houston et al. 2012, Frison, Boirie et al. 2015).

The findings of reduced all-cause mortality (Burr, Fehily et al. 1989, Mozaffarian, Lemaitre et al.
2013), primary cardiac arrest (Siscovick, Raghunathan et al. 1995, Mozaffarian and Wu 2011) and
coronary heart disease mortality (Kromhout, Bosschieter et al. 1985) have been demonstrated with
fish intakes of 2 meals per week. The current dietary recommendations of 2 fish meals per week
are in line with the earlier findings (National Health and Medical Research Council 2013).

As well as the aforementioned prevention of cardiovascular disease, there is experimental evidence
of the effects of fish oil that could pertain to some of the effects of aging on cardiac and muscle
function. Fish oil supplementation has shown promise in the attenuation of the age related changes
in muscle mass, strength and muscle protein metabolism (Smith, Atherton et al. 2011, Rodacki,
Rodacki et al. 2012, Hutchins-Wiese, Kleppinger et al. 2013, Krzymińska-Siemaszko, Czepulis et
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al. 2015, Smith, Julliand et al. 2015, Da Boit, Sibson et al. 2017). However, these studies have
supplemented at therapeutic doses with EPA-rich fish oil capsules so it is not known whether the
findings from these studies are achievable through dietary intake of 1-2 fish meals per week.

Evidence suggests that the long chain omega-3 polyunsaturated fatty acid (LC n-3 PUFA),
docosahexaenoic acid (DHA), incorporates into human heart and skeletal muscle (Metcalf, James
et al. 2007, McGlory, Galloway et al. 2014) and incorporation of DHA leads to positive changes
within those tissues, which may benefit aging adults. In animal models, low doses of LC n-3
PUFA, in particular DHA, significantly incorporate into myocardial and muscle membranes,
suggesting that membrane incorporation can occur through fish oil doses approximating 2 fish
meals per week (Slee, McLennan et al. 2010, Henry, Peoples et al. 2015). Supplementing DHArich fish oil capsules in humans at 2 grams per day significantly incorporates into red blood cells,
reflective of heart and skeletal muscle membranes (Macartney, Hingley et al. 2014, Hingley,
Macartney et al. 2017), thus supporting animal evidence and demonstrating that incorporation into
membranes is possible through DHA-rich fish oil approximating 2 fish meals per week.

This project combined a small cohort study and a randomised control trial to examine the potential
benefits of LC n-3 PUFA in aging physiology. A small cohort study first explored the physiology
of aging and in particular the energy cost of walking in a group of adults aged 60-85 years. In those
identified as deficient in LC n-3 PUFA, a randomised control trial aimed to increase the omega-3
status using a dietary achievable dose of high-DHA tuna fish oil capsules to improve physical
function, including walking speed, underpinned by the modulation of oxygen consumption and
cardiovascular function.

3

1.2

Functional decline with age
1.2.1

Sarcopenia and declining strength

Sarcopenia is characterised by a progressive loss of muscle mass and strength as an individual ages
(Cruz-Jentoft, Baeyens et al. 2010), which accelerates beyond the age of 70 years (Ganse, Ganse
et al. 2018). Sarcopenia is associated with increased mortality (Landi, Cruz-Jentoft et al. 2013),
increased falls risk (Tanimoto, Watanabe et al. 2014), and reduced quality of life (Beaudart,
Reginster et al. 2015, Trombetti, Reid et al. 2016). Currently, slowing sarcopenia is a primary
focus for reducing disability, reducing mortality, increasing mobility and quality of life in older
aged adults.

Lifestyle interventions which include modifying nutrition and physical activity behaviours have
an important role in slowing the progression of age related muscle and strength loss (Witard,
McGlory et al. 2016). Physical activity interventions which focus on incorporating higher
intensities of exercise such as resistance training improves muscle strength, balance, endurance,
and time to fatigue (Ferketich, Kirby et al. 1998, Ferreira, Sherrington et al. 2012). With respect
to nutritional intervention there has been a focus on protein and energy intake to combat nutritional
frailty through counteracting ‘anabolic resistance’ with age (Breen and Phillips 2011, Moore,
Churchward-Venne et al. 2015). Strategies which have addressed the quantity and frequency of
protein consumption, and more specifically leucine-rich protein sources, along with kilojoule-rich
supplements have produced promising results in the attenuation of skeletal muscle loss and
strength loss, as well as the augmentation of muscle protein synthesis in older adults, especially
when coupled with physical activity (Turic, Gordon et al. 1998, Paddon-Jones and Rasmussen
2009, Moore 2014, Moore, Churchward-Venne et al. 2015, Paddon-Jones, Campbell et al. 2015,
Murphy, Oikawa et al. 2016, Murphy, Saddler et al. 2016). Whilst, with merit, muscle size and
4

strength share an important role in attenuating sarcopenia, relatively little attention has been given
to the physiological cost of performing exercise in the aged adult, despite compelling evidence
that oxygen efficiency of heart and skeletal muscle are linked to exercise related fatigue (Schrack,
Simonsick et al. 2010). Recent research emphasising the concept of oxygen modulation, primarily
displayed through walking speed now provides new potential to address declining function in older
age (Schrack, Zipunnikov et al. 2016).

1.2.2

Cardiovascular decrements during aging

With age there are declines in cardiovascular system performance which includes changes in its
structure, function and its ability to handle physiological stress such as ischemia (Strait and Lakatta
2012). The structural changes that occur include thickening of the left ventricular wall and arterial
stiffness, which negatively influences the heart’s contractile efficiency (Gerstenblith, Frederiksen
et al. 1977, Grodzicki, Michalewicz et al. 1998). The accelerated decline in cardiovascular
function, and more specifically, aerobic capacity that is associated with age has wide reaching
ramifications in older life (Fleg, Morrell et al. 2005). Functional independence of an older adult
depends heavily on their ability to perform activities of daily living at the lowest physiological
cost and perceived effort of activity. When the physiological cost of walking, expressed as volume
of oxygen consumed per heartbeat, is reduced it leads to higher engagement of free-living physical
activity and less sedentary behaviours (Carter, Hunter et al. 2018). Ischaemic preconditioning
refers to the heart’s intrinsic process of resisting damage and limiting blood and oxygen supply to
organ systems during ischemia. It is noted that with age, the hearts intrinsic ability to resist damage
is reduced (Juhaszova, Rabuel et al. 2005). Nutritional strategies which incorporate omega-3 fatty
acids have demonstrated a similar preconditioning effect on the heart (Abdukeyum, Owen et al.
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2008), which may be of importance due to the decline in the heart’s own intrinsic ability seen with
age.

There are a number of clinically attainable measures directly pertaining to the heart such as resting
heart rate and heart rate recovery following exercise which are now understood to have a strong
association with future disease prediction. Resting heart rate is a useful heart measure due to its
ease of use in clinical settings and its strong prognostic importance in mortality and cardiovascular
risk (Cooney, Vartiainen et al. 2010, Saxena, Minton et al. 2013). In elderly populations, an
elevated heart rate is a predictor of cardiovascular death, whereas a lower heart rate is related to
better health outcomes (Palatini, Casiglia et al. 1999). Whilst resting heart rate provides valuable
information about the cardiovascular system, its collection may be influenced by external factors
relating to environmental stimuli such as room light (Smolders, de Kort et al. 2012), body position
(Watanabe, Reece et al. 2007) and psychological factors (Mancia, Bertinieri et al. 1983).
Therefore, a measure of heart rate which is collected in more controlled manner, such as during
night-time sleep, appears to serve as a stronger measure in determining mortality and
cardiovascular risk in elderly populations (Johansen, Olsen et al. 2013). Therefore, in order to
comprehensively assess the heart rate profile, one primary objective of the current study was to
collect ECG quality depolarisation across a range of conditions pertaining to rest, exercise and
recovery.

6

1.2.3

Oxygen cost of exercise and the impact of aging

The de-adaptation of oxygen delivery and oxygen utilisation systems with age has an important
role in physical activity output due to the role that oxygen availability and uptake has as a regulator
of developed tension and fatigue (Hogan, Arthur et al. 1992, Burtscher 2013). The energy cost of
walking increases with age (Wert, Brach et al. 2013), leaving a lower energy reserve for additional
activities throughout the day whereby the “physical cliff” occurs, characterised by a rapid
acceleration in the decline in physical activity across 24 hours that occurs from mid to late life
(Schrack, Zipunnikov et al. 2014). Brought on initially by the heightened physiological cost of
activity, this trend for lower activity towards the end of the day results from higher self-perceived
effort and fatigue to activity and the subsequent avoidance of further activity to conserve energy
(Fleg, Morrell et al. 2005).

In older adults, preferred walking speeds of 0.8 meters per second (m/s) predicts mortality and
adverse health outcomes (Abellan van Kan, Rolland et al. 2009). Walking speeds over 1.0m/s
suggests better than average life expectancy and improvements in activities of daily living, with
speeds over 1.2m/s suggesting exceptional life expectancy (Abellan van Kan, Rolland et al. 2009,
Studenski, Perera et al. 2011). This has been confirmed in the Invecchiare in Chianti (InCHIANTI)
study which reported physical inactivity and walking speed as the frailty criteria showing the
strongest associations with muscle density and muscle mass (Cesari, Leeuwenburgh et al. 2006).
75% of Australian adults aged over 65 years old report being insufficiently active (did not meet
the minimum recommended physical activity guidelines) and therefore are at a heighted risk of
physical function declines (Australian Bureau of Statistics 2015). It is established that older adults
who are physically active and partake in habitual exercise have a slower decline in physical
function (Westerterp 2000, Riebe, Blissmer et al. 2009). Taken together, these findings highlight
7

the importance of maintaining physical activity and walking speeds as an individual ages in order
to combat declines in muscle mass and quality of life.

Measuring walking speed is a cost effective, clinically relevant and practical field test which is
suggested for routine measurement as an additional vital sign in older adults (Middleton, Fritz et
al. 2015). Walking speed is easily administered by health professionals and has strong predictive
power across a range of adverse health events in aged populations such as cardiovascular events
(Matsuzawa, Konishi et al. 2013) and cardiovascular mortality (Dumurgier, Elbaz et al. 2009),
frailty (Castell, Sanchez et al. 2013), falls (Montero-Odasso, Schapira et al. 2005) and survival
rates (Studenski, Perera et al. 2011), as well as being a good marker of functional status (Verghese,
Wang et al. 2011). Therefore, the current study has assessed the physiology of walking in older
adults and the potential to modulate this by increasing DHA intake via a DHA-rich fish oil
supplement at a dose that is equivalent to consuming 2 fatty fish meals per week.

1.3

The influence of diet and nutrition behaviours on health and longevity

Diet behaviors, diet quality and the composition of macronutrients within the diet are known to
influence health outcomes and life expectancy (Wirt and Collins 2009). Currently, the country
with the highest life expectancy is Japan (World Health Organization 2018). When assessing
Japanese dietary habits there are key elements which may influence their longevity. Japanese diets
comprise higher fish consumption relative to western culture, as well as lower energy density of
food sources relative to nutrients (Ministry of Health Labour and Welfare Japan 2014, Murakami,
Livingstone et al. 2017). Adherence to the Japanese dietary guidelines resulted in lower overall
mortality and cardiovascular mortality (Kurotani, Akter et al. 2016). Diets such as the
Mediterranean diet which share similar characteristics with Japanese culture, including high fish
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consumption and intake of nutrient rich foods, reduce the risk of all-cause and cause-specific
mortality (Burr, Fehily et al. 1989, Knoops, de Groot et al. 2004). The InCHIANTI study, a large
population-based study of older Italians, determined that, upon measurement of plasma LC n-3
PUFA concentration, an indicator of fish consumption, participants with the highest levels of
plasma LC n-3 PUFA were also deemed to have the highest functional status (Abbatecola,
Cherubini et al. 2009). Another population study conducted in older adults, The Three-CityBordeaux Study, also found a positive association between walking speed and plasma LC n-3
PUFA concentrations, with particular importance to the higher proportion of DHA (Frison, Boirie
et al. 2015). Therefore, it is plausible that a diet that allows provision for LC n-3 PUFA naturally
derived from fish intake, has a mechanistic basis, such as modulation of skeletal muscle and
cardiac function achieved by cell membrane incorporation of specific fatty acids to improve
function of contractile tissue, such as heart and skeletal muscle (McLennan, Owen et al. 2007,
Peoples and McLennan 2010). This warrants further investigation and is a primary focus of this
thesis.

1.4

Fish oil providing long-chain omega-3 polyunsaturated fatty acids

Dietary fish oil incorporates long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) into
cardiac (Metcalf, James et al. 2007) and skeletal muscle membranes (Andersson, Nalsen et al.
2002, McGlory, Galloway et al. 2014), with a dominance for DHA incorporation into fast twitch
(type II) fibres (Henry, Peoples et al. 2015). Incorporation of LC n-3 PUFA into cardiac muscle
cells reduces heart rate and improves myocardial oxygen efficiency (Pepe and McLennan 2002,
McLennan, Owen et al. 2007, Hidayat, Yang et al. 2017). In animals, feeding LC n-3 PUFA
reduces skeletal muscle fatigue and improves skeletal muscle oxygen consumption (Peoples and
McLennan 2010, Peoples and McLennan 2014). These effects, initially observed after higher
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doses, have been replicated with dietary achievable doses of fish oil in animals (Henry, Peoples et
al. 2015) and young adults (Hingley, Macartney et al. 2017). DHA enrichment, following low
doses of fish oil (2g/day) improves heart rate recovery after intense exercise (Macartney, Hingley
et al. 2014) and lowers the oxygen cost of exercise in trained male participants (Hingley,
Macartney et al. 2017).

1.4.1

Fish consumption: Current intakes and trends

The suggested dietary target (SDT) from The National Health and Medical Research Council
(NHMRC) for LC n-3 PUFA is 430mg/d for females and 610mg/d for males (National Health and
Medical Research Council 2006). These suggested targets closely relate to a fish intake of 2 fish
meals per week (providing LC n-3 PUFA of approximately 430-570 mg/d) (National Health and
Medical Research Council 2006). However, the suggested dietary targets are not based on a
physiological or nutrition effect but rather on the 90th percentile of usual intake.

In Australia, the mean LC n-3 PUFA intake of older adults (>65 years) has increased more than 2fold between 1995 and 2012 (Meyer 2016). Current mean LC n-3 PUFA intakes for adults over
65 years are 494mg/d for females and 441mg/d for males. Despite an increase in the mean intake
of LC n-3 PUFA, the current median LC n-3 PUFA intake in older adults is well below the SDT.
The median LC n-3 PUFA intake in older adults is approximately 120mg/d, and overall less than
20% of Australians are meeting the SDT (Meyer 2016). When dietary guidelines which include
adequate fish consumption are adhered to, such as in Japan, there is a clear benefit in reducing
mortality and more specifically, cardiovascular mortality rates (Kurotani, Akter et al. 2016).
Therefore, it is possible that supplemental fish oil which is in line with dietary achievable amounts
may benefit cardiovascular outcomes in older adults.
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1.4.2

Fish oil and cardioprotection

Fish oil, providing omega-3 fatty acids have been a topic of debate regarding its efficacy and role
in cardiovascular disease risk and mortality. Strong evidence suggests that when clinical trials are
appropriately designed, that is, to have strict exclusion criteria, be powered to detect changes in
primary outcome measures and to have accurate measures of circulating LC n-3 PUFA before and
after the trial, that there is a clear relationship between fish intake and cardio-protection. Early
population-based and observation studies established links between fish consumption and reduced
risk of cardiovascular related health issues (Bang, Dyerberg et al. 1971, Kromhout, Bosschieter et
al. 1985, Siscovick, Raghunathan et al. 1995). Evolutionary work in the 1970’s set the hypothesis
that the high consumption of seafood consumed by the Greenlandic Inuit’s was responsible for
their low cardiovascular disease occurrence (Bang, Dyerberg et al. 1971). There is a recurring
notion throughout early studies that 1-2 fish meals per week are able to improve cardiovascular
outcomes. Kromhout et al., (1985) established an inverse, dose-response relationship between fish
consumption and death from coronary heart disease after a 20 year follow up. Researchers
determined that fish consumed at a frequency of 1-2 fish meals per week has preventative power
of over 50% for coronary heart disease mortality. Siscovick et al., (1995) supported these findings,
whereby fish consumption at a frequency of 1-2 fish meals per week in their study was associated
with a 50% reduction in primary cardiac arrest. Furthermore, and of particular importance to the
current study, in middle-aged and elderly men, consumption of fish weekly reduces the risk of
fatal myocardial infarction (Yuan, Ross et al. 2001) and cardiovascular risk factors when fish is
consumed twice per week (Mizushima, Moriguchi et al. 1997). The earlier findings of the cardioprotective role of LC n-3 PUFA from fatty fish have been supported in larger population studies
such as The DART Trial which established that 2 fish meals per week reduces the risk of all-cause
mortality (Burr, Fehily et al. 1989), and the GISSI-Prevenzione Trial, which included 11,324
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participants who had survived recent myocardial infarction and when given LC n-3 PUFA had
decreased rates of death, non-fatal myocardial infarction and stroke over 3.5 years follow up
(Valagussa 1999).

It has been demonstrated that a low intake of fish oil is sufficient to provide LC n-3 PUFA
incorporation in myocardial membranes in rats with a preference for DHA incorporation (Slee,
McLennan et al. 2010) and that this leads to altered myocardial effects such as an anti-arrhythmic
action on the heart (McLennan, Abeywardena et al. 1988, Pepe and McLennan 1996, Pepe and
McLennan 2002). Incorporation of LC n-3 PUFA into cardiac muscle cells reduces heart rate and
improves myocardial oxygen efficiency even in isolated hearts (Pepe and McLennan 2002,
McLennan, Owen et al. 2007). These findings provide evidence for a direct cardioprotective effect
on the heart as a result of LC n-3 PUFA incorporation into myocardial membranes. In humans,
DHA selectively lowers heart rate in healthy men (Grimsgaard, Bonaa et al. 1998) and in mildly
hyperlipidemic men (Mori, Bao et al. 1999), and offers a nutritional approach to modifying
cardiovascular disease risk, specifically pertaining to cardiac origin.

1.4.3

Fish oil and sarcopenia

Fish oil has gained attention as a key nutrient in a range of age related health issues, including
bone health, cognitive decline, and muscular function (Molfino, Gioia et al. 2014). Attempts at
combatting sarcopenia with fish oil supplementation have targeted the known declines in muscle
strength and size, as well as anabolic resistance with age (Smith, Atherton et al. 2011, Rodacki,
Rodacki et al. 2012, Hutchins-Wiese, Kleppinger et al. 2013, Di Girolamo, Situlin et al. 2014,
Krzymińska-Siemaszko, Czepulis et al. 2015, Smith, Julliand et al. 2015, Da Boit, Sibson et al.
2017, Alfaddagh, Elajami et al. 2018).
12

Smith et al., (2011) worked with a small sample of older adults (n=15) to investigate the effects of
a high-EPA, high-dose fish oil supplement (4g/day) taken for 8 weeks on muscle protein synthesis.
Researchers found that basal muscle protein synthesis was not influenced by fish oil
supplementation,

however

fish

oil

did

augment

the

anabolic

response

from

the

hyperaminoacidemia-hyperinsulinemia induced increase in the rate of muscle protein synthesis.
This study established that fish oil supplementation, albeit at a dose not likely reproduced through
dietary fish intake alone, incorporated significantly into muscle phospholipids in older adults.

The role of physical activity, and more importantly strength training for the prevention of falls,
attenuation of muscle mass and strength loss, as well as improved quality of life in the elderly is
well established (Ferketich, Kirby et al. 1998, Persch, Ugrinowitsch et al. 2009, Mayer, ScharhagRosenberger et al. 2011, Ferreira, Sherrington et al. 2012). Building on the hypothesis from Smith
et al., (2011) that fish oil has anabolic signalling properties in older adults, Rodacki et al., (2012)
combined fish oil supplementation with strength training in older women to determine whether
fish oil may augment the benefits of strength training. In contrast to Smith et al., (2011), this study
used a dietary achievable dose of fish oil taken over 12 weeks, however, this study included only
women, was not placebo-controlled and all groups performed strength training throughout the
study. The fish oil group achieved a significant incorporation of EPA and DHA into plasma
phospholipids. The increase in EPA was twice as much as DHA. This was likely due to the EPArich fish oil capsule used in the study. Fish oil was effective at increasing peak torque and rate of
torque development in the knee flexor/extensor and plantar/dorsiflexor above what was seen in the
group who performed strength training alone. Given that greater rate of torque development in the
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knee flexor muscle group is associated with less falls in the elderly (Bento, Pereira et al. 2010),
this suggests that LC n-3 PUFA from fish oil has the potential to decrease falls risk with age when
coupled with strength training. The participants in this study were all sedentary females at baseline
so the findings may not extend to older populations with a higher activity level and which include
males. In fact, Da Boit et al., (2017) sought to determine whether there were sex differences in
how a high-dose, high-EPA fish oil supplement may augment adaptations to resistance training in
an active group of older males and females. Fish oil does indeed seem to increase resistance
training adaptations to a greater extent in females compared to males, as seen by Da Boit et al.,
(2017), where only the female group receiving fish oil increased peak torque and muscle quality
(strength generated per unit of muscle mass). However, it should be noted that there was no
measure of dietary intake. The importance of dietary intake, especially when combined with
resistance training in older adults is well established and therefore consideration of controlling
dietary intake should be accounted for in light of the reported findings (Mori and Tokuda 2016).

In a later study by Smith et al., (2015), participants were supplemented with the same high-dose
(4g/day), high-EPA fish oil capsule as used in their 2011 study, however now researchers
investigated whether 3 months or 6 months of fish oil supplementation improves muscle mass and
muscle strength in older adults. Interestingly, fish oil supplementation only influenced muscle
strength after 6 months, whereas it was unchanged at the 3 month time point. In addition,
participants in the control group decreased their muscle thigh volume and muscle strength to a
similar extent that the fish oil group increased their muscle thigh volume and muscle strength.
Given that participants in this study were healthy and active older adults it is not known why this
occurred. Since there was no measure of physical activity or dietary intake before or after the
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intervention, it is difficult to know whether changes in activity level or dietary intake may have
influenced these findings. When fish oil was supplemented at a dose reproduceable through dietary
intake of approximately 2 fish meals per week (~2g/day), Krzyminska-Siemaszko et al., (2015)
did not find any changes in muscle mass or muscle strength in older adults with decreased muscle
mass after 12 weeks. This study, however, did not measure circulating levels of EPA or DHA
before or after supplementation. Without a measure of baseline and post-supplement levels of EPA
and DHA, either within muscle tissue or circulating levels in plasma or red blood cells, it is
impossible to establish whether participants had the same levels of LC n-3 PUFA at baseline, or
whether the intervention caused a change post supplementation. Nonetheless, similar results were
found when blood levels of EPA and DHA were measured by Hutchins-Wiese et al., (2013) who
supplemented older females who met pre-frail or frail criteria with a low dose (2g/day) fish oil
supplement and not find any changes in strength measures as a result of fish oil supplementation.
Taken together, it appears that high-dose fish oil primarily augments strength-related increases
only when combined with resistance training and the effect is greater in females.

To date, research involving omega-3 fatty acids to combat sarcopenia and improve muscle function
in the elderly have used EPA-rich capsules which do not reflect fatty acid profiles of fresh fish,
which is higher in DHA (Smith, Atherton et al. 2011, Rodacki, Rodacki et al. 2012, HutchinsWiese, Kleppinger et al. 2013, Krzymińska-Siemaszko, Czepulis et al. 2015, Smith, Julliand et al.
2015, Da Boit, Sibson et al. 2017, Alfaddagh, Elajami et al. 2018), have used doses which exceed
amounts achievable through food alone (Smith, Atherton et al. 2011, Smith, Julliand et al. 2015,
Da Boit, Sibson et al. 2017, Alfaddagh, Elajami et al. 2018), or did not measure LC n-3 PUFA
within muscle phospholipids or blood to ensure participants start with low levels of omega-3 fatty
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acids, to match intervention and control groups at baseline and to establish a change in muscle or
blood levels as a result of fish oil supplementation (Krzymińska-Siemaszko, Czepulis et al. 2015,
Alfaddagh, Elajami et al. 2018).

A range of factors need to be considered when conducting research involving omega-3 fatty acids,
including doses that are high enough to see an effect in the outcome measures within a manageable
population sample, but also achievable through diet. Additionally, a measurement of baseline
blood fatty acids to ensure participants start with low circulating omega-3 concentrations, and to
match control and intervention groups to ensure no significant differences at baseline. The present
study used a finger prick method to collect blood for determination of the omega-3 index in red
blood cells (Harris and Von Schacky 2004). The omega-3 index is a measure of the proportion of
EPA plus DHA in red blood cell membranes and a low omega-3 index has been proposed as a
cardiovascular risk factor. The omega-3 index is inversely associated with risk for coronary heart
disease (Harris and Von Schacky 2004) and there are now proposed target ranges which may
further classify risk. An omega-3 index value over under 4% is suggested be high risk, between
4% and 8% indicates an intermediate risk, whereas over 8% suggests low risk and provides the
greatest cardio-protection (Harris 2008). To date, little work has been done to investigate whether
the omega-3 index improves cardiovascular measures not relating to mortality rates, such as heart
rate. Elevating the omega-3 index lowers heart rate in depressed patients with coronary heart
disease and in cardiac transplant patients (Harris, Gonzales et al. 2006, Carney, Freedland et al.
2010), however it is unclear whether an elevated omega-3 index in older adults has a similar effect
of lowering heart rate. As it relates to older adults, the omega-3 index is inversely associated with
performance-based test results (Fougere, de Souto Barreto et al. 2018), however little work has
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been done on cardiovascular outcomes such as heart rate in this population. Therefore, the current
study will attempt to determine whether elevating the omega-3 index using a dietary achievable
dose of fish oil in older adults will improve heart rate during rest, exercise and night time sleep.

1.4.4

Fish oil and oxygen efficiency

The role of omega-3 fatty acids in oxygen modulation within skeletal muscle (Peoples and
McLennan 2010, Peoples and McLennan 2014, Henry, Peoples et al. 2015) provides a nutritional
target for reducing oxygen cost of exercise, freeing up energy reserve and reducing fatigue. In
humans, Logan et al., (2015) dealt with functional measures such as the timed up and go test in
older age females, with improvements being found in the group supplemented with fish oil.
Despite showing improvements in physical function outcomes, the dosage of 5g/d of fish oil used
in the Logan et al., (2015) study is difficult to attain through diet alone and would require
supplementation. Therefore, the current study adopted a fish oil intake of 2g/d of DHA-rich tuna
fish oil capsules (delivering 140 mg of EPA and 560 mg of DHA per day) which translates to
approximately 2 fish meals per week in order to determine if dietary achievable fish intakes may
improve physical function outcomes.

Of particular importance to aging, DHA incorporates greater relative concentrations in fast-twitch
muscle fibres (type II) compared to slow twitch muscle fibres (type I) (Henry, Peoples et al. 2015).
There is a general shift towards lower levels of planned physical activity and higher levels of
sedentary behaviour across all age groups in Australia. This is particularly evident in adults aged
65 and over, showing marked declines in overall and vigorous physical activity (Australian Bureau
of Statistics 2015). Increased levels of moderate to vigorous physical activity significantly
counteracts sarcopenia (Mijnarends, Koster et al. 2016). The reduction of vigorous activities with
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age may perhaps be due to the dominant atrophy of fast-twitch (type II) muscle fibres relative to
slow-twitch (type I) muscle fibres (Deschenes 2004). Type II muscle fibres are responsible for
engagement in higher intensities of activity. Using a DHA-rich fish oil capsule, this study proposed
that the incorporation of DHA into skeletal muscle will reduce fatigue and energy costs of walking,
leading to a greater energy reserve to improve participation in physical activity.

1.5

Aims and hypothesis

To date, improvements in cardiac and skeletal muscle function have been investigated in animal
models or in healthy, young adults. Due to the low doses of fish oil required to significantly
improve membrane DHA incorporation in animals (Slee, McLennan et al. 2010, Henry, Peoples
et al. 2015) and healthy younger adults (Macartney, Hingley et al. 2014, Hingley, Macartney et al.
2017), this study tested the feasibility that low dose DHA-rich fish oil can elevate the omega-3
index in older adults and therefore improve heart rate profiles at rest and during exercise and
recovery. Furthermore, as a result of an elevated omega-3 index and the expected changes to
skeletal muscle membranes it is feasible that the oxygen cost of exercise will be lowered and
physical function improved.

Aim 1: Determine whether a low dose DHA-rich fish oil supplement would improve the omega-3
index in older adults over the course of 16 weeks. The dose delivered LC n-3 PUFA DHA
(560mg/day) and EPA (140mg/day) and was equivalent to consuming 1-2 fish meals per week.

Hypothesis 1: It was hypothesised that a DHA-rich fish oil supplement would significantly modify
the whole blood and specifically the erythrocyte membranes to reflect LC n-3 PUFA DHA in the
diet and therefore elevate the omega-3 index.
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Aim 2: Investigate whether an increased omega-3 index will improve heart rate profiles at rest and
during exercise and recovery in older adults.

Hypothesis 2: Due to the established role of omega-3 fatty acids in cardiac protection, it was
hypothesised that an elevated omega-3 index would lower heart rate, independent of autonomic
nervous system function, at rest and during exercise and recovery in older adults.

Aim 3: Determine if an elevated omega-3 index modifies the oxygen cost of exercise and improves
physical function, in particular walking speed, in older adults.

Hypothesis 3: It was hypothesised that DHA-rich fish oil supplementation would lower the oxygen
cost of exercise and improve physical function.
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2.

General Methods

2.1

Study design

This study was a double-blind design with placebo control. Older adults, aged 60-85 years were
supplemented for 16 weeks with either 2 grams per day of DHA-rich tuna fish oil or placebo oil
(Sunola). The DHA-rich tuna fish oil provided long chain omega-3 fatty acids achievable in the
human diet via the consumption of 2 fatty fish meals per week. Physiological status and physical
function were measured at baseline and following the 16 weeks of supplementation. Approval for
ethics was applied for in April 2016 from the University of Wollongong Human Research Ethics
Committee and approved in July 2016 (HE16/169).

2.2

Experimental overview

Selected participants attended the University of Wollongong’s Exercise Physiology Patient
Simulation Laboratory for baseline (week 0) and post-supplement (week 16) assessments. Each
visit was approximately 2.5 hours in duration. Baseline testing included physiological and physical
function assessments and ambulatory heart rate monitoring. Participants who reported a fish
consumption of 2 fish meals or more per week were excluded at baseline. Participants meeting all
the inclusion criteria were then randomly allocated to either a control (Sunola oil) or intervention
(DHA-rich fish oil) group delivered as 1 gram capsules. Each participant consumed 2 grams of oil
per day over the duration of the 16 weeks. The physiological and physical function assessments
and ambulatory heart rate monitoring performed at baseline were repeated after 16 weeks. The
experimental overview is shown in figure 2.1.
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Figure 2.1. Experimental overview
Abbreviations: PUFA, polyunsaturated fatty acid; ECG, electrocardiogram.
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2.3

Participant recruitment and selection

Physically active participants, aged between 60-85 years, were required for the study in order to
complete the range of physical assessments. Participants were recruited from local physical
recreation facilities (including tennis clubs, lawn bowling clubs, cycling clubs and walking clubs),
and the University of the Third Age within the Illawarra region of Australia. Participants were able
to ambulate without an assistive device.

Each participant completed a series of questionnaires which were;
•

The Physical Activity Readiness Questionnaire (PAR-Q) to determine whether participants
were physically able to perform physical activity and to limit adverse events,

•

The International Physical Activity Questionnaire – Elderly (Hurtig-Wennlof, Hagstromer
et al. 2010) to establish their baseline physical activity level and to enable detection of
physical activity change by the end of the intervention;

•

The Pittsburgh Fatigability Scale (Glynn, Santanasto et al. 2015) to understand
participants’ self-perceived mental and physical fatigue, as well as any change by the end
of the intervention;

•

The Mini-Nutritional Assessment – Short Form (MNA®-SF) (Vellas, Guigoz et al. 1999)
to determine whether participant’s were at risk of being malnourished (reporting a score
<12).

Participants were also screened for medications that directly affect the cardiovascular system (for
example, Beta Blockers).

In addition, participants performed a pulmonary function test using a hand held spirometry device
(ParvoMedics, USA). This assessment was conducted both before and after the supplementation
period. The pulmonary function test focused on the main reported determinants of respiratory
fitness and health; forced expiratory volume in 1 second (FEV1) (L) which measured the amount
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of air that was forcefully exhaled within the first second of the test and forced vital capacity (FVC)
(L) which measured the total amount of air exhaled during the test (Sin, Jones et al. 2004, Sin, Wu
et al. 2005). Participants were initially familiarised with the procedure. Each participant was
instructed to perform the test twice, with a 1 minute break between attempts. On each attempt they
were instructed to take a full breath in, to fill the lungs, and then rapidly exhale as quickly and
forcefully as possible. If there was a greater than 10% difference between force expiratory volume,
they were provided with a third attempt. If this was the case, the best attempt was taken as the final
result. The recruitment and screening process is detailed, with reasons for exclusion at each step
in figure 2.2.

There were a number of exclusion criteria that was applied to ensure physically active participants
who also described as having low intakes of long chain omega-3 fatty acids. For the former,
participants were excluded if they had, (i) difficulty performing daily living activities, (ii) history
of active cancer in last 3 years, (iii) recent or planned major surgery, (iv) currently smoking, (v)
uncontrolled hypertension, (vi) dyslipidaemia, (vii) Body Mass Index (BMI) <18 or >32, or (viii)
lung health indicative of COPD. Reference criteria of >70% FEV1/FVC was used (Hardie, Buist
et al. 2002) and participants who did not meet this criteria were excluded. For the latter,
participants were also excluded if they reported using omega-3 and or fish oil supplements in the
last 6 months or, based upon preliminary screening using the food frequency questionnaire (FFQ)
specific for omega-3 and omega-6 food sources (Swierk, Williams et al. 2011) they were identified
as consistently consuming up to 2 fish meals per week. Ultimately, red blood cell omega-3 index
(EPA+DHA) was the tool used to determine omega-3 status.
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Figure 2.2. Participant screening, recruitment and completion flow chart.
Details of the withdrawals and exclusion are included on the far right hand side of the figure.
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2.4

Participant allocation to groups

The participants were matched for characteristics such as age, sex and BMI as well as several
primary outcome measures. These included 400m walk time (m/s), resting heart rate (bpm), and
the omega-3 index (percentage of EPA and DHA in red blood cells).

In terms of allocation to supplement, neither the participants nor the research student was informed
of the specific group allocation, thus making the study double blinded. The primary supervisor
allocated the capsules to each of the participants and the capsules were provided in colour-coded
blister packs. Instructions for taking the capsules were provided in the package and this included
consuming with a meal.

2.5

Dietary supplementation

The control group were supplemented with 2 grams per day of Sunola oil which delivered 160mg
per day of the n-6 PUFA linoleic acid (18:2n-6) and 1620mg per day of monounsaturated oleic
acid (18:1n-9). The intervention group (FO) were supplemented with 2 grams per day of DHArich, tuna fish oil capsules, which delivered 140mg of EPA and 560mg of DHA per day (700mg
per day total). Fatty acid composition tables are provided in table 2.1 for Sunola Oil and DHArich tuna fish oil.
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Table 2.1. Major fatty acid percentage composition of the dietary supplements used in the study
Dietary Supplement
Sunola Oil
Fatty Acid
(Control)
∑ Saturated Fatty acids
9.0
∑ Mono-unsaturated Fatty acids
81.0
∑ Minor Fatty acids
∑ Omega-6 PUFA
8.0
18:3n-3
20:5n-3
22:5n-3
22:6n-3
∑ Omega-3 PUFA
-

Fish Oil
31.7
21.4
6.1
6.3
0.6
5.3
1.1
25.0
34.6

Abbreviations: 18:3n-3, alpha-linoleic acid; 20:5n-3, eicosapentaenoic acid; 22:5n-3,
docosapentaenoic acid; 22:6n-3, docosahexaenoic acid. Fatty acid composition provided by
Clover Corporation Ltd. Minor fatty acids include fatty acids which were unidentified from the
standard.
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3.

Laboratory assessments

3.1

Overview

The following assessments were completed both before and after the supplementation period of
16 weeks. On arrival at the Exercise Physiology Laboratory, participant anthropometrics were
initially recorded according to International Standards for Anthropometrics. A 3-lead
electrocardiogram was attached to their chest for electrocardiograph screening by an Accredited
Exercise Physiologist (Australian Exercise and Sport Science Association). Resting heart rate and
blood pressure were collected, in a supine position over 5 minutes duration, prior to physical
assessments and a muscle oxygen monitor was secured to their gastrocnemius muscle (medial
head). Upon meeting the pre-screening requirements (see exclusion criteria, section 1.3) they then
began their dietary assessments and the senior fitness tests which included grip strength, bicep curl
repetitions, sit to stand repetitions, timed up and go, and walking speed measured over 20m and
400m. Finally, participants completed a submaximal treadmill test, followed by a controlled
recovery phase. The entire assessment took approximately 2.5 hours.

3.2

Anthropometry and participant preparation

Participant’s body mass and height were measured using anthropometric scales (SECA875 flat
scale, SECA, United Kingdom) and stadiometer (SECA217 Stable Stadiometer, SECA, United
Kingdom) with the participant lightly clad and shoes off. A Polar heart rate strap (Model RS800CS,
Polar, Kempele, Finland) was placed across the chest of the participants and remained on
throughout the duration of their visit in order to continually collect recordings of heart rate. Blood
pressure was recorded on the left arm of the participant, in a supine position, using an OMRON
home monitoring device (Model Omron IA2, Omron Healthcare Co, Kyoto, Japan).
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Continuous wave near-infrared spectroscopy (NIRS) was used to determine relative changes in
local muscle oxygen saturation (SmO2) during rest and exercise. A muscle oxygen monitor
(MOXY Fortiori Design, Minnesota) was placed on the gastrocnemius muscle (medial head) of
the dominant lower limb with black non-adhesive bandage tape placed on top of the monitor to
prevent external light from influencing readings. An elastic Velcro wrap secured the monitor to
the limb and prevented movement during activity.

3.3

Assessment of nutritional status and dietary intake

Nutritional status of participants was assessed using the Mini Nutritional Assessment – Short Form
(MNA®-SF) which served as a screening instrument at baseline. The MNA®-SF is a valid tool for
people over 65 years. It uses a point scoring system ranging from 0-14 to determine nutritional
adequacy. In order for participants to continue in the study they needed to score between 12-14,
deemed ‘normal nutrition status’. Dietary assessment involved an electronically administered
combined food frequency questionnaire (FFQ) specific for omega-3 and omega-6 food sources
(Swierk, Williams et al. 2011). The food frequency questionnaire took approximately 15-20
minutes to complete.

A 3-day food record was administered to participants at baseline and post supplementation.
Participants were instructed to record and approximate the serving size of all food and beverages
consumed for breakfast, lunch and dinner, including any snacks for 3 consecutive days which
included 2 week days and 1 weekend day. Participants were instructed to maintain usual eating
and drinking habits and were not required to weigh foods, but were asked to provide household
measurements for foods consumed (i.e. cups, tablespoons). Food records were returned to the
laboratory at their next visit where they were checked for accuracy and completion, in addition to
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asking the participant further questions such as portion sizes and drinks consumed. Data was
manually entered into FoodWorks 8 (Xyris Software, Australia) diet and nutrition analysis
software. The Ausbrands 2016 and Ausfoods 2016 databases were used. Data was then exported
to Microsoft Excel (2016) for analysis, which included determining the average daily intake of
participants at baseline and post supplementation.

3.4

Senior fitness assessments

A battery of physical fitness tasks were performed before and after the supplementation period.
The Senior Fitness Test is an accepted and validated combination of functional tasks that can be
scored according to normative values (Rikli and Jones 1999).

3.4.1

30 second arm curl

Upper body strength and endurance was assessed with the 30 second arm curl test. The participant
braced their upper (dominant) arm against their body whilst they curled the weight up and down.
A 2kg weight was used for female participants and a 3kg weight was used for male participants.
The total number of complete arm curls (up and down equal’s 1 curl) within 30 seconds was
recorded.

3.4.2

Grip strength

Maximal isometric hand and forearm strength (kg) were assessed using a hand dynamometer and
pinch dynamometer. For the hand grip strength test, participants were instructed to exert maximal
force for 5 seconds using a hand dynamometer (SM-K3 series, Total Patient Care, Sydney,
Australia). This was performed twice on both dominant and non-dominant arms and the highest
value was recorded for analysis. Participants were instructed to perform a pinch grip strength test
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using the lateral/key punch method. Hand-held dynamometry and pinch test has good test-retest
reliability and concurrent validity in older community dwelling persons (Abizanda, Navarro et al.
2012).

3.4.3

30 second Chair stand

The 30 second chair stand test assessed leg strength and endurance. Participants began in a seated
position with their hands across their chest and were instructed to stand up with their knees fully
locked out and hands still across their chest before returning to the seated position. This was
repeated as many times as possible within 30 seconds. The total number of completed chair stands
(up and down equals 1 stand) within 30 seconds was recorded.

3.4.4

Time up and go

The timed up and go test assessed the participant’s speed, agility and balance whilst moving.
Participants were instructed to stand, walk to the cone (2 meters in front), turn around and walk
back to a seated position. The time (seconds) between the initial seated position to the return to
seated position was recorded. This test was performed twice and the fastest recording used for
analysis.

3.5

Walking assessments

Walking speed was assessed under 3 conditions: i) self-selected walking speed over 20m, ii)
walking rapidly over 20m, and iii) the 400m rapid walk test. The 20m walk protocols followed the
design used by Shahar (2012). Participants were instructed to walk at their usual pace for 1 return
lap (20m) between cones placed 10m apart and then as fast as they can for the same distance. For
the 400m rapid walk test, participants walked between 2 distance markers placed 10m apart.
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Participants walked as quickly as possible between cones placed 10m apart until they completed
400m in total. Their time (in minutes and seconds) of completion was recorded, in addition to time
taken every 40m (seconds).

Following the 400m walk test, participants were immediately returned to a seated position for 2
minutes for heart rate recovery determination.

3.5.1

Experimental measures and analysis
3.5.1.1.

Speed

Walking speed during the 400m walk test was calculated for each 40m lap (meter per second), in
addition to the overall time to complete the 400m walk test.

3.5.1.2.

Heart rate

Heart rate continuously measured on a beat to beat basis (ventricular depolarisation) during the
400m walk test was downloaded to the Polar Protrainer 5 software program (Finland). The files
were then converted to text files which allowed them to be imported into Kubios heart rate
variability program (Department of Physics of the University of Kuopio, Finland) where they were
analysed. Heart rate was averaged on a lap by lap basis, in addition to an overall mean for the
entire walk test.

Heart rate recovery following the 400m walk test was assessed as the beat reduction from their
final heart rate during the 400m walk test and their heart rate at 1 minute post and 2 minutes post
walk test.
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3.5.1.3.

Muscle Oxygen

Continuous wave near-infrared spectroscopy (NIRS) was used to determine relative changes in
local muscle oxygen saturation (SmO2) during rest and exercise. The near-infrared spectroscopy
device measured muscle tissue saturation by emitting near-infrared light (wavelength, 680-800nm)
into the muscle tissue. Reflected near-infrared light from the tissue is received by 2 near-infrared
spectroscopy detectors positioned 12.5 and 25mm away from the light source and allows accurate
readings of muscle oxygenation through ~12mm of skin and adipose tissue. The near-infrared
spectroscopy device used an algorithm created from a Monte Carlo model of light traveling
through layers of tissue consisting of the epidermis, dermis, adipose and muscle tissue. The
algorithm is designed for high sensitivity to the muscle layer and low sensitivity to everything else.

Muscle oxygen saturation was collected at 2 second intervals during the 400m walk. Near-infrared
spectroscopy data files were downloaded as Microsoft Excel files. Resting tissue saturation index
was calculated by averaging the final minute of the pre-exercise seated rest. Exercise tissue
saturation was determined by averaging each 40m lap as well as the overall mean for the 400m
walk test. A spreadsheet was created to calculate relative tissue saturation index for each lap by
using the following equation,

𝐸𝑥𝑒𝑟𝑐𝑖𝑠𝑖𝑛𝑔 𝑇𝑆𝐼 − 𝑅𝑒𝑠𝑡𝑖𝑛𝑔 𝑇𝑆𝐼

Equation 1: (

𝑅𝑒𝑠𝑡𝑖𝑛𝑔 𝑇𝑆𝐼

) × 100
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3.6

Submaximal treadmill test

The submaximal treadmill assessment was designed to elicit a controlled external work rate which
was increased via firstly an increase in speed (stage 1) and secondly and increase in gradient (stage
2). The treadmill speed for each participant was initially set to the pre-defined relative speeds
determined during the 400m walk. Pre-exercise resting measures were collected with the
participant in a seated position, followed immediately by the submaximal treadmill protocol. Heart
rate and whole body oxygen consumption were measured continuously. On completion of the
treadmill protocol, participants were required to recover in a standardized supine position. This
assessment was also completed before and after the supplementation period.

3.6.1

Pre-exercise

The protocol began with participants seated for 5 minutes. Participants were required to breathe
normally and remain quiet. Pre-exercise resting measures, including heart rate, oxygen
consumption and muscle oxygen saturation were continuously measured.

3.6.2

Treadmill protocol

Following the pre-exercise resting phase, participants were moved to the treadmill to begin the
submaximal walking protocol. The protocol was adapted from the Balke Treadmill Test (Balke
and Ware 1959) and consisted of 2 stages. Stage 1 lasted 9 minutes and began on a 1% gradient.
Adjustments were made to treadmill speed, increasing by 0.5km/h every 3 minutes, reaching a
peak speed which was calculated as 70-75% of maximum 400m walking speed. Stage 2 lasted 6
minutes and during stage 2 the treadmill gradient increased by 2% every 3 minutes, reaching a
final gradient of 5% during the last 3 minutes. Treadmill speed remained constant during stage 2.
Heart rate, RPE, oxygen consumption and muscle oxygen saturation were continuously measured.
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3.6.3

Post treadmill recovery phase

After completing the treadmill walk, participants were immediately moved to a plinth where they
lay supine for a period of 10 minutes with room lights turned off. There were no external influences
such as noise or movement and participants were asked to remain quiet and still during the 10
minute recovery phase.

3.6.4

Experimental measures and analysis
3.6.4.1.

Heart rate

Heart rate was continuously collected on a beat to beat (ventricular depolarisation) basis during
the visit. Heart rate data was downloaded to the Polar Protrainer 5 software program (Finland).
The files were then converted to text files which allowed them to be imported into Kubios heart
rate variability program (Department of Physics of the University of Kuopio, Finland) where they
were analysed. Resting heart rate was calculated as the average heart rate during the last 3 minutes
of the pre-exercise seated rest. Exercise heart rate for stage 1 and stage 2 was determined by
averaging the final 60 seconds of each stage, respectively.

3.6.4.2.

Heart rate recovery

Heart rate recovery after the completion of the treadmill protocol was determined by applying a
logit transformation model to the recovery heart rate values which allowed for a single phase model
of half recovery times to be established (Stupnicki, Gabrys et al. 2010). This method allows
comparisons between participant’s time to half recovery (t1/2). A spreadsheet was created in
Microsoft Excel (2016) which allowed instantaneous heart rate values to be plotted at predetermined intervals during the 10 minute supine recovery phase, in addition to overnight
minimum heart rate and exercising peak rate heart rate. Heart rates were plotted at every 15 second
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mark for the first 3 minutes, followed by at every 30 second mark for the next 3 minutes and finally
at every 60 second mark for the remaining 4 minutes of supine recovery. Following this, the net
difference between the overnight resting heart rate and the instantaneous heart rates was calculated.
An example of this step using trial data is shown . The net heart rate values were then converted
to log transformed values. An example using trial data is shown figure 3.2. Finally log transformed
data was converted to decimal logit values using the following recommended formula (89):
Equation 2: 𝑙𝑜𝑔𝑖𝑡(𝑥𝑖 ) = 𝑙𝑜𝑔(𝑥

𝑥𝑖
𝑚 −𝑥𝑖

)

Where xi is the net value of heart rate at time point i, and xm is the peak heart rate.

From here a half time was established from the time to half intercept. An example using trial data
is shown in figure 3.3.
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Figure 3.1. Net heart rate (mean ± SEM) during post-exercise recovery.
Data taken from baseline assessments to represent the net heart rate drop after the submaximal
treadmill protocol. Recovery time immediately following exercise is shown in seconds on the xaxis. Net heart rate which was calculated as peak heart rate minus minimum heart rate is shown
on the y-axis in beats per minute.

2 .1 0

lo g ( h e a r t r a t e )

2 .0 0
1 .9 0
1 .8 0
1 .7 0
1 .6 0
1 .5 0
1 .4 0
1 .3 0
1 .2 0
0

100

200

300

400

500

600

R e c o v e r y tim e ( s e c o n d s )

Figure 3.2. Heart rate log values (mean ± SEM) during post-exercise recovery.
Data taken from baseline assessments to represent the log heart rate drop after the submaximal
treadmill protocol. Recovery time immediately following exercise is shown in seconds on the xaxis. Net heart rate values were logged and they are shown on the y-axis.
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Figure 3.3. Logit heart rate values (mean ± SEM) during post-exercise recovery.
The value of log time at logit = 0 corresponds to log half-recovery time (t1/2).
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3.6.5

Muscle oxygen

Muscle oxygen saturation was collected at 2 second intervals for the entire visit. Near-infrared
spectroscopy data files were downloaded as Microsoft Excel files. Resting tissue saturation index
was calculated by averaging the last 3 minutes of the pre-exercise seated rest. Exercise tissue
saturation for stage 1 and stage 2 was determined by averaging the final 60 seconds of each stage,
respectively. A spreadsheet was created to calculate relative tissue saturation index for each
treadmill stage by using the following equation,

𝐸𝑥𝑒𝑟𝑐𝑖𝑠𝑖𝑛𝑔 𝑇𝑆𝐼 − 𝑅𝑒𝑠𝑡𝑖𝑛𝑔 𝑇𝑆𝐼

Equation 3: (

3.6.6

𝑅𝑒𝑠𝑡𝑖𝑛𝑔 𝑇𝑆𝐼

) × 100

Oxygen consumption

Participants were fitted with a Hans Rudolf two-way non-rebreathing face mask (Hans Rudolf inc,
Kansas, USA). Respiratory data was collected over a 15 second rolling average during seated rest
and during the treadmill protocol using expired gas analysis (Parvo Medics TrueOne® 2400
Metabolic Measurement System, Utah, USA). The system was calibrated daily using a 2-point
calibration of room air (21% oxygen, 0.03% carbon dioxide) and scientifically graded gas (15.87%
oxygen, 4.03% carbon dioxide). Breath by breath data sampled included oxygen consumption,
carbon dioxide production, tidal volume, breathing frequency, inspiratory duration, and expiratory
duration. Resting oxygen consumption was collected during the 5 minute pre-exercise seated rest
and the final 3 minutes were averaged and used for analysis. A single sample of the final 60 second
oxygen consumption at each treadmill stage was calculated and along with work rate, was used to
determine oxygen cost of exercise. Net oxygen consumption was calculated by subtracting the
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resting oxygen consumption from the gross oxygen consumption during the final 60 seconds of
each treadmill stage.

Work rate was calculated using the following equation,
𝑊𝑜𝑟𝑘 𝑟𝑎𝑡𝑒 (𝑘𝑔. 𝑚. 𝑚𝑖𝑛 − 1) =

(𝑏𝑜𝑑𝑦 𝑚𝑎𝑠𝑠 × (𝑠𝑖𝑛𝑒 𝑎𝑛𝑔𝑙𝑒 × 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒))
3 𝑚𝑖𝑛𝑢𝑡𝑒𝑠

Finally, net oxygen consumption and work rate were used to determine oxygen cost of
walking.

𝐶𝑜𝑠𝑡 𝑜𝑓 𝑤𝑎𝑙𝑘𝑖𝑛𝑔 (𝑚𝐿. 𝑚 − 1) =

3.6.7

𝑁𝑒𝑡 𝑜𝑥𝑦𝑔𝑒𝑛 𝑐𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛 (𝑚𝐿/𝑘𝑔/𝑚𝑖𝑛)
𝑊𝑜𝑟𝑘 𝑟𝑎𝑡𝑒 (𝑘𝑔/𝑚/𝑚𝑖𝑛)

Rating of perceived exertion

The 15-point Borg Rating of Perceived Exertion (RPE) scale was used to measure participant’s
subjective exercise intensity (where 6 = very, very light, 20 = very, very hard) (Borg 1982).
Participants were asked “how hard are you exercising” within the last 60 seconds of each treadmill
stage.

3.7

Blood sample collection and storage

Whole blood sample (plasma, white blood cells, platelets, and red blood cells) collection was
performed before and after the 16 weeks of supplementation using a dried blood spot method
(OmegaQuant, South Dakota, United States). This test is a minimal burden form of blood sampling
which

has

been

validated

per

the Guidance

for

Industry:

Bioanalytical

Method
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Evaluation (FDA; May, 2001) and previously used to determine omega-3 concentrations in red
blood cell membranes (Johnston, Deuster et al. 2013, Baack, Puumala et al. 2015). The finger of
the participant was cleaned with an alcohol swab. A lancet containing a spring-loaded needle was
used to collect the blood spot. A drop of blood was collected on filter paper that was pre-treated
with an antioxidant cocktail (Fatty Acid Preservative Solution, FAPS™) and allowed to dry at room
temperature for 15 minutes. Samples were stored at -80 degrees celsius and then shipped to
OmegaQuant Analytics for fatty acid analysis. One hole punch of the dry blood spot was
transferred to a screw-cap glass vial followed by addition of BTM (methanol containing 14%
boron trifluoride, toluene, methanol; 35:30:35 v/v/v) (Sigma-Aldrich, St. Louis, MO). The vial
was briefly vortexed and heated in a hot bath at 100˚C for 45 minutes. After cooling, hexane (EMD
Chemicals, USA) and HPLC grade water was added, the tubes were recapped, vortexed and
centrifuged help to separate layers. An aliquot of the hexane layer was transferred to a GC vial.
GC was carried out using a GC-2010 Gas Chromatograph (Shimadzu Corporation, Columbia, MD)
equipped with a SP-2560, 100-m fused silica capillary column (0.25 mm internal diameter, 0.2 um
film thickness; Supelco, Bellefonte, PA).

Fatty acids were identified by comparison with a standard mixture of fatty acids characteristic of
RBC (GLC OQ-A, NuCheck Prep, Elysian, MN) which was also used to construct individual fatty
acid calibration curves. The following 24 fatty acids (by class) were identified: saturated (14:0,
16:0, 18:0, 20:0, 22:0 24:0); cis monounsaturated (16:1, 18:1, 20:1, 24:1); trans (16:1, 18:1*, 18:2*
- see below for more details); cis n-6 polyunsaturated (18:2, 18:3, 20:2, 20:3, 20:4, 22:4, 22:5); cis
n-3 polyunsaturated (18:3, 20:5, 22:5, 22:6). Fatty acid composition was expressed as a percent of
total identified fatty acids. The omega-3 index is defined as the sum of 20:5n-3 (EPA) and 22:6n-
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3 (DHA) adjusted by a regression equation (r = 0.97) to predict the omega-3 index in the RBC
(Johnston, Deuster et al. 2013).
*The chromatographic conditions used in this study were sufficient to isolate the C16:1trans
isomers and the C18:2  9t-12c, 9t-12t, and 9c-12t isomers; the latter is reported as C18:2n6t.
However, each individual C18:1 trans molecular species (i.e., C18:1 6 thru 13) could not be
separated but appeared as 2 blended peaks that eluted just before oleic acid. The areas of these 2
peaks were summed and referred to a C18:1 trans.
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4.

Ambulatory cardiac monitoring

4.1

Overview

Ambulatory cardiac monitoring was carried out before and after the supplementation period.
Participants were fitted with a wearable cardiac monitor (eMotion Faros 180) which is a low
burden device that collects ECG quality heart recordings (Mega Electronics Ltd, Finland). The
device consists of a small sensor and 3 cables with disposable electrode patches (Ambu BlueSensor
VLC Electrodes, Ballerup Denmark). Participants were required to wear the monitor for 24 hours
in order to capture overnight sleep on at least 1 night.

4.2

Protocol

Participants were fitted with the cardiac monitor prior to leaving the laboratory in accordance with
manufacturer recommendations. The first electrode (right arm) which contained the portable
monitor was placed in the 2nd intercostal space medial to the right deltoid. The second electrode
(left arm) was placed in the 2nd intercostal space medial to the left deltoid. The third electrode (left
leg) was placed between the left pectoral muscle and the iliac crest. Participants were asked to
remove the monitor if it may come in contact with water (e.g. swimming, showering), and then
return the monitor and electrodes to the same position once finished. Additional electrode patches
were provided to participants in order to reattach the device after water based activities.

4.3

Analysis

ECG and activity data from the monitor were downloaded as EDF files to the desktop. The
downloaded files were then imported into HRV-Scanner Software (Biosign, Ottenhofen
Germany). The files were placed through an automatic filter which is part of the HRV-Scanner
program. Filtering removed artefacts and noise from the signal. Sleep was determined when the
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accelerometer which is built in to the device recorded an extended supine period. The trace was
visually inspected for when heart rate became steady and analysis started from the beginning of
that point. Overnight R-R times were collected and heart rate and heart rate variability was
calculated over both the entire night as well a 10 minute period during the night where heart rate
was at its lowest. The lowest 10 minute period was determined by visual inspection of the trace.
Time, nonlinear, and frequency parameters were analysed for heart rate variability. In addition, the
ratio between overnight heart rate and awake resting heart rate was calculated to assess the degree
of nocturnal dip that occurs.

4.3.1

Time domain heart rate variability

Time domain parameters measured during the entire sleep period as well as during the lowest 10
minute period during the night were the standard deviation of NN intervals (SDNN), and the root
mean square of the successive differences (RMSSD) of NN intervals. The SDNN reflects longterm cyclic components responsible for variability in the recording period. The RMSSD represents
short term dynamic changes in beat to beat variability and is a good indicator of sympathovagal
balance (Otzenberger, Gronfier et al. 1998).

4.3.2

Nonlinear domain heart rate variability

A Poincaré plot was used for quantitative-visual analysis of beat-to-beat variability. The Poincaré
plot is a scattergram of the current RR interval plotted as a function of the previous one. An ellipse
is then fitted along the line of identity to the plot and is used to determine SD1 and SD2 (figure
4.1). Dispersion of the points perpendicular to the line of identity are represented by SD1 which is
an index of instantaneous beat-to-beat variability (parasympathetic) (Kamen, Krum et al. 1996).
The points along the line of identity are represented by SD2. The length of the SD2 along the line
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of identity reflects continuous beat-to-beat variability (sympathetic) (Brennan, Palaniswami et al.
2002). The ratio of SD1:SD2 is considered to represent sympathovagal balance.

4.3.3

Frequency domain heart rate variability

The heart rate variability signal from the time series analysis was transformed with the Fourier
transformation to allow spectral analysis. The transformed data was then able to be analysed on a
frequency scale. High-frequency spectrum included frequencies between 0.15 and 0.40Hz. Lowfrequency spectrum included frequencies between 0.04 and 0.15Hz. Very-low-frequency included
frequencies of 0.04Hz and lower. The high-frequency band reflects parasympathetic activity,
whereas the low-frequency band predominantly reflects sympathetic activity (Shaffer, McCraty et
al. 2014).
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Figure 4.1. Example of a Poincaré plot generated from baseline data
RR interval is shown on the x-axis (RRn). The subsequent RR interval is plotted on the y-axis
(RRn+1). SD1 represents dispersion of points perpendicular to the line of identity and indicates
parasympathetic activity (Kamen, Krum et al. 1996). SD2 represents point along the line of
identity and indicates sympathetic activity (Brennan, Palaniswami et al. 2002).
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4.4

Experimental standardisation

All experimental laboratory trials were conducted in the University of Wollongong’s exercise
physiology patient simulation laboratory (room temperature 22°C, 35% relative humidity).
Assessments requiring an additional room were conducted at the UniActive Sports Centre
(University of Wollongong), which is a temperature-controlled room. Participants were instructed
to consume 10 millilitres of water per 1kg body weight prior to testing to maintain hydration status.
Testing equipment used during the visits was prepared and calibrated prior to participant arrival.

4.5

Statistical analysis

Using a power of 0.8, an estimated average standard deviation of 3, and the ability to detect a 4
beat per minute difference in resting heart rate, a minimum number of 8 participants per group was
calculated. To allow for a 20% drop-out rate, 10 participants per supplement group were recruited
for this study. Analysis of the collected data was conducted using the Statistix 10 for Windows
(Analytical Software, Tallahassee FL, USA) and Graphpad (Prism 5, La Jolla, CA, USA) software
packages. For association relationships, a linear regression model was applied to the relevant
variables. For outcome measures directly pertaining to the primary aims of the study, a repeated
measures analysis of variance (ANOVA) was used, with diet supplement (control, fish oil groups)
and time (baseline and 16-week post treatment condition) main effects, and supplement * time
interaction. In addition, mean differences between pre- and post-supplementation for the control
group compared to the mean differences pre- and post-supplementation for the DHA-rich fish oil
group were analysed by one way ANOVA. Where significant difference was established, a post
hoc Tukey or Bonferroni analysis was conducted for comparisons of individual means. The data
was expressed as mean (standard deviation) for participant characteristics or mean (standard error)
for outcome measures. Alpha was set at P<0.05.
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5.

Results

5.1

Demographics and functional capacity

Twenty two participants were tested at baseline and their data was used to explore age related
physical function and physiology. This cross-section cohort represented healthy and physically
active older adults. Not only were they free from chronic disease, including major cardiovascular
and respiratory dysfunction, they were also of high physical function and walking speed. Their
baseline data is presented in table 5.1.
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Table 5.1. Anthropometric and physiology data at baseline for the entire cohort.

Anthropometric
Number
Age (y)
Height (m)
Weight (kg)
BMI (kg/m2)
MNA®-SF score
Cardiovascular
SBP (mmHg)
DBP (mmHg)
Heart rate (bpm)
Physical Function
Left grip (kg)
Right grip (kg)
Left pinch (kg)
Right pinch (kg)
Sit to stand (reps)
Time up and go (s)
Bicep Curl (reps)
Walking Speed
20m usual speed (m/s)
20m rapid speed (m/s)
400m speed (m/s)

Male

Female

Combined

9
71 (2)
1.70 (0.02)
77.39 (2.63)
26.98 (1.13)
13.63 (0.14)

13
70 (2)
1.59 (0.01)
58.05 (2.29)
22.98 (1.01)
13.46 (0.66)

22
70 (1)
1.63 (0.02)
65.96 (2.67)
24.62 (0.85)
13.52 (0.60)

134 (4)
76 (2)
66 (3)

131 (4)
74 (2)
68 (2)

132 (3)
75 (2)
67 (2)

32.89 (2.79)
34.78 (2.57)
8.94 (0.61)
9.22 (0.71)
21.56 (2.33)
4.13 (0.23)
22.33 (1.75)

17.77 (1.24)
17.81 (1.41)
5.42 (0.37)
5.73 (0.36)
17.15 (0.93)
4.46 (0.22)
17.46 (1.14)

23.96 (2.09)
24.75 (2.24)
6.86 (0.50)
7.16 (0.51)
18.96 (1.17)
4.33 (0.16)
19.46 (1.09)

1.28 (0.02)
1.89 (0.09)
1.64 (0.06)

1.24 (0.05)
1.73 (0.06)
1.49 (0.05)

1.26 (0.03)
1.79 (0.05)
1.55 (0.04)

Cardiovascular parameters measured supine at rest; Sit to stand = no. of reps in 30s; Timed up
and go = stand – 4m walk – sit; Bicep curl = lifting 2kg (female), 3kg (male) No. reps in 30s;
400m speed = average speed over 400m walking. Values are mean (SEM). Abbreviations: BMI,
body mass index; MNA®-SF, Mini-Nutritional Assessment – Short Form; SBP, systolic blood
pressure; DBP, diastolic blood pressure.
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Data from the International Physical Activity Questionnaire are presented in table 5.2. Participants
achieved an average of 79 minutes of moderate intensity physical activity per day which far
exceeded the recommended 30 minutes of moderate intensity physical activity on most, preferably
all, days for older adults (Australian Government 2013).

Table 5.2. International Physical Activity Questionnaire data for males (n=9) and females
(n=13) at baseline for the entire cohort (n=22).

IPAQ
Walking min
Walk MET-min
Moderate activity min
Moderate MET-min
Vigorous activity min
Vigorous MET-min
Total MET-min

Male

Female

542 (119)
1789 (656)
640 (324)
2562 (1295)
246 (65)
1968 (523)
6320 (1597)

851 (204)
2810 (673)
493 (95)
1975 (379)
108 (59)
867 (470)
5653 (1163)

Combined
725 (146)
2392 (482)
553 (140)
2215 (560)
164 (45)
1318 (362)
5926 (927)

Self-reported physical activity data over 7 days. Values are mean (SEM). Abbreviations: MET,
metabolic equivalent of task.
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5.2

The oxygen cost of walking in the older adult

The relationship between self-selected walking speed collected during the 20m and 400m walk
tests and anthropometric measures, in addition to self-reported physical activity and the oxygen
cost of walking collected during stage 1 and stage 2 of the treadmill protocol was assessed using
linear regression. Height was positively associated with 20m rapid and 400m rapid walking speeds,
but not usual walking speed (table 5.3). Age and BMI was not significantly associated with any
walking speed.

There was a significant inverse relationship between usual and rapid walking speed over 20m and
400m and the oxygen cost of walking at stage 1 (increasing speed) and stage 2 (increasing gradient)
of the treadmill protocol, whereby participants with lower oxygen cost of walking achieved faster
walking speeds (table 5.4, figure 5.1).
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Table 5.3. Association between walking speed and age, height and BMI for the entire cohort
(n=22).
Age
(y)
R2
Walking Speed
20m usual speed (m/s)
20m rapid speed (m/s)
400m rapid speed (m/s)

0.14
0.14
0.17

Height
(m)
R2
0.02
0.28*
0.31**

BMI
(kg/m2)
R2
0.01
0.04
0.01

*P<0.05, **P<0.01. Abbreviations: BMI, body mass index.

Table 5.4. Association between walking speed and treadmill oxygen cost of walking.
Treadmill oxygen cost of walking
(mL/m)
Treadmill Stage 1
Treadmill Stage 2
2
R
R2
Walking speed
20m usual speed (m/s)
20m rapid speed (m/s)
400m rapid speed (m/s)

0.37**
0.35**
0.26*

0.11
0.39*
0.36*

*P<0.05, **P<0.01. Treadmill stage 1 (n=19), treadmill stage 2 (n=15).
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Figure 5.1. Linear regression of 20m usual walking speed and oxygen cost of walking at (A)
stage one (A) and stage two (B) of treadmill walking, 20m rapid walking speed and oxygen cost
of walking at stage one (C) and stage two (D) of treadmill walking, and 400m rapid walking
speed and oxygen cost of walking at stage one (E) and stage two (F) of treadmill walking.
Treadmill stage one (n=19), treadmill stage two (n=15).
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Linear regression of the oxygen cost of walking and the absolute heart rate during the treadmill
protocol at stage 1 and stage 2 are presented in table 5.5. The oxygen cost of walking was
significantly associated with heart rate during both stages of the treadmill protocol, whereby the
greater the oxygen cost of walking, the greater the heart rate had to be to provide oxygen (table
5.5, figure 5.2).

Table 5.5. Linear regression of heart rate and oxygen cost of walking during the treadmill
protocol.
Treadmill oxygen cost of walking
(mL/m)
Treadmill Stage 1 Treadmill Stage 2
R2
R2
Heart rate (bpm)
Treadmill Stage 1
Treadmill Stage 2

0.44**
0.57**

**P<0.01. Treadmill stage 1 (n=19), treadmill stage 2 (n=15).
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Figure 5.2. Linear regression of heart rate and oxygen cost of walking at stage one (A) and stage
two (B) of the treadmill protocol.
Treadmill stage one (n=19), treadmill stage two (n=15).
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Data from self-reported physical activity and fatigue collected from the International Physical
Activity Questionnaire – Elderly and the Pittsburg Fatigability Scale and the oxygen cost of
walking during the submaximal treadmill protocol are presented in table 5.6. There were no
significant relationships for either self-reported physical activity or fatigue and oxygen cost of
walking during the treadmill protocol.

Table 5.6. Linear regression of treadmill oxygen cost of walking and self-reported physical
activity and fatigue.
Treadmill oxygen cost of walking (mL/m)
Treadmill Stage 1
Treadmill Stage 2
2
R
R2
IPAQ
Walk MET-min
Moderate MET-min
Vigorous MET-min
Total MET-min
PFS
Physical fatigue
Mental fatigue

0.01
0.01
0.06
0.02

0.01
0.03
0.08
0.06

0.01
0.01

0.15
0.01

Treadmill stage 1 and IPAQ (n=19), treadmill stage 2 and IPAQ (n=16). Treadmill stage 1 and
PFS (n=17), treadmill stage 2 and PFS (n=14). Abbreviations: IPAQ, International Physical
Activity Questionnaire; MET, metabolic equivalents of task; PFS, Pittsburgh Fatigability Scale.
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5.3

Agreement between self-reported nutrition data and blood fatty acids

To determine whether self-reported nutrition data reflected red blood cell fatty acids, a linear
regression model was used for the PUFA FFQ and for the 3-day food record and corresponding
red blood cell fatty acids at baseline. There was no relationship at baseline between red blood cell
markers and self-reported LC n-3 PUFA from the PUFA FFQ (table 5.7) or the 3-day food record
(table 5.8).

Table 5.7. Relationship between whole blood fatty acids and red blood cell equivalent omega-3
index and self-reported fatty acids from the PUFA food frequency questionnaire.
Whole blood fatty acids
EPA
DHA EPA+DHA
2
R
R2
R2
PUFA FFQ
EPA (g/d)
DHA (g/d)
EPA+DHA (g/d)
EPA+DHA (g/d)

RBC EPA+DHA
Omega-3 index
R2

0.09
0.02
0.09
0.02

P-value

0.28
0.60
0.28
0.28

N=15. Abbreviations: EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; PUFA,
polyunsaturated fatty acid; FFQ, food frequency questionnaire

To determine whether there was a relationship between the two self-reported collection tools and
their reporting of long chain fatty acids, the PUFA food frequency questionnaire and the 3-day
food record were assessed for agreement. There was no significant relationship between these two
measures (table 5.9).
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Table 5.8. Relationship between whole blood fatty acids and red blood cell equivalent omega-3
index and self-reported fatty acids from the 3-day food record.
Whole blood fatty acids
EPA
DHA EPA+DHA
2
R
R2
R2
3-day food record
EPA (g/d)
DHA (g/d)
EPA+DHA (g/d)
EPA+DHA (g/d)

RBC EPA+DHA
Omega-3 index
R2

P-value

0.00

0.95
0.74
0.72
0.72

0.01
0.01
0.01

N=14. Abbreviations: EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.

Table 5.9. Relationship between self-reported fatty acids from the 3-day food record and PUFA
food frequency questionnaire.
PUFA FFQ (g/d)
EPA
DHA
EPA+DHA P-value
2
2
R
R
R2
3D-Food Record
EPA (g/d)
DHA (g/d)
EPA+DHA (g/d)

0.01
0.01
0.01

0.71
0.91
0.79

N=14. Abbreviations: EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; PUFA,
polyunsaturated fatty acid; FFQ, food frequency questionnaire.
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5.4

Agreement between physical function and blood fatty acids

There was a significant relationship between right hand pinch strength and whole blood DHA
(P<0.05) (table 5.10). Left hand pinch strength was significantly associated with DHA,
EPA+DHA, and the omega-3 index (P<0.05) (table 5.10). No other significant relationships were
identified between the long chain omega-3 fatty acid and walking capacity.

Table 5.10. Relationship between whole blood fatty acids and red blood cell equivalent omega-3
index at baseline and heart rate, oxygen cost of treadmill walking, walking speed, and grip
strength.
Whole blood fatty acids

HR stage 1 treadmill walking (bpm)
HR stage 2 treadmill walking (bpm)
Oxygen cost of treadmill walking
stage 1 (mL/m)
Oxygen cost of treadmill walking
stage 2 (mL/m)
20m usual speed (s)
20m rapid speed (s)
400m rapid speed (s)
Right hand grip strength (kg)
Left hand grip strength (kg)
Right hand pinch strength (kg)
Left hand pinch strength (kg)

RBC
EPA+DHA
R2
Omega-3
index
0.01
0.03

21
16

R2

R2

EPA

DHA

0.10
0.01

0.01
0.03

R2
EPA+
DHA
0.01
0.03

0.13

0.01

0.02

0.02

19

0.01

0.01

0.01

0.01

15

0.01
0.01
0.10
0.02
0.01
0.01
0.03

0.03
0.03
0.03
0.11
0.13
0.19*
0.27*

0.01
0.02
0.08
0.10
0.10
0.10
0.23*

0.01
0.02
0.08
0.10
0.10
0.10
0.23*

21
21
21
22
22
22
22

N

*P<0.05. Subject numbers are reported in the table for each variable. Abbreviations: EPA,
eicosapentaenoic acid; DHA, docosahexaenoic acid; HR, heart rate.
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5.5

Fish oil supplementation and the effects on physiological and physical function

Of the 22 participants tested at baseline, 21 met inclusion into the study. One participant had a
high self-reported fish consumption and was excluded. Of the 21 participants that met inclusion,
2 participants chose not to continue following the baseline assessments. Therefore, 19 participants
were allocated to a supplement group. By 16 weeks, 1 participant was excluded due to noncompliance (self-reported increase in a fish oil supplement) and 1 participant had a baseline
omega-3 index >8% which was confirmed via blood sample analysis. This resulted in 17
participants, who met all the criteria, successfully completing the 16 week trial (89% completion
rate). This included 8 participants for the control group and 9 participants for the fish oil group.
Anthropometric and demographic data are presented in table 5.11. The study recruitment and
participant completion is shown in figure 2.2.

Table 5.11. Anthropometric and demographic data, before and after supplementation.
Control
Pre
Anthropometric
Age (y)
Height (m)
Weight (kg)
BMI (kg/m2)

Fish Oil
Post

Pre

70 (1)
1.62 (0.02)
65.75 (4.88)
24.95 (1.57)

1.62 (0.02)
66.43 (4.86)
25.21 (1.55)

Post
70 (1)

1.65 (0.03)
67.03 (4.13)
24.78 (1.44)

1.65 (0.03)
66.43 (4.00)
24.59 (1.47)

Control (n=8), fish oil (n=9). Values are mean (SEM). Abbreviations: BMI, body mass index.
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5.6

Diet assessment

Data from the 3-day food record are presented in table 5.12. All participants met the estimated
energy requirements (EER) for their age, body mass index and activity level (National Health and
Medical Research Council 2006). Participants exceeded the recommended dietary intake (RDI)
for protein in older adults based on weight which is 1.07g/kg for males (~80g/d), and 0.94g/kg for
females (~56g/d). In addition, participants also exceeded the protein intake that is advised for
physically active older adults of 1.2g/kg (Bauer, Biolo et al. 2013), however they were still within
the suggested dietary target of no more than 25% of protein as energy (National Health and
Medical Research Council 2006). Participants consumed approximately 1.6g/kg of protein in the
current study. There were no significant differences in any nutrient at baseline or after
supplementation (P>0.05).
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Table 5.12. Nutrition data collected from the 3-day food record for control (n=7) and fish oil
(n=7) groups.

Energy (kJ/d)
Protein (g/d)
Fat (g/d)
Saturated fat (g/d)
Trans fat (g/d)
Polyunsaturated fat (g/d)
Linoleic acid (g/d)
a-linoleic acid (g/d)
EPA (g/d)
DPA (g/d)
DHA (g/d)
Monounsaturated fat (g/d)
Cholesterol (mg/d)
Carbohydrate (g/d)
Sugar (g/d)
Fiber (g/d)
% Energy (kJ) from Protein
% Energy (kJ) from Fat
% Energy (kJ) from Carbohydrate
Ash (g/d)
Thiamin (mg/d)
Riboflavin (mg/d)
Niacin (mg/d)
Vitamin C (mg/d)
Vitamin E (mg/d)
Vitamin B6 (mg/d)
Vitamin B12 (µg/d)
Total Folate (µg/d)
Folic acid (µg/d)
Total Vitamin A (µg/d)
Sodium (mg/d)
Potassium (mg/d)
Magnesium (mg/d)
Calcium (mg/d)
Phosphorus (mg/d)
Iron (mg/d)
Zinc (mg/d)

Control
Pre
Post
8967 (802)
8977 (488)
106 (9)
105 (9)
88 (11)
82 (6.9)
30 (3)
25 (3)
1.3 (0.2)
1.1 (0.2)
17.0 (4.2)
14.7 (2.6)
13.5 (3.5)
11.8 (1.5)
2.9 (0.8)
1.7 (0.6)
0.2 (0.1)
0.3 (0.2)
0.1 (0.0)
0.2 (0.1)
0.2 (0.1)
0.4 (0.2)
34 (4)
36 (3)
229 (31)
239 (58)
205 (17)
226 (19)
109 (12)
103 (9)
40 (7)
33 (3)
20.2 (1.1)
19.9 (1.3)
35.9 (1.3)
33.6 (2.3)
37.7 (1.4)
41.6 (2.5)
20.2 (1.6)
17.2 (1.7)
2.0 (0.2)
1.9 (0.4)
3.0 (0.2)
2.0 (0.2)
25.9 (3.3)
25.7 (3.6)
211 (601)
137 (38)
16.3 (3.2)
13.1 (2.5)
2.0 (0.3)
2.0 (0.2)
5.6 (0.6)
4.5 (0.6)
960 (374)
465 (32)
143 (33)
148 (33)
1294 (203)
986 (302)
1930 (154)
2025 (409)
4444 (506)
3642 (221)
506 (64)
415 (25)
1312 (108)
813 (92)
1932 (157)
1670 (147)
14.5 (1.6)
13.2 (1.1)
11.9 (0.9)
10.9 (0.7)

Fish Oil
Pre
Post
11051 (950)
11048 (832)
116 (7)
114 (18)
107 (11)
126 (20)
34 (3)
35 (6)
1.3 (0.1)
1.3 (0.2)
20.9 (4.4)
26.0 (5.5)
17.4 (3.5)
21.6 (5.0)
2.7 (0.8)
2.5 (0.6)
0.2 (0.1)
0.6 (0.5)
0.1 (0.0)
0.2 (0.2)
0.2 (0.1)
0.8 (0.6)
43 (4)
56 (10)
285 (41)
252 (64)
259 (30)
212 (22)
139 (21)
84 (12)
51 (10)
36 (4)
18.2 (1.2)
17.8 (2.9)
35.8 (1.8)
41.2 (3.6)
37.7 (1.8)
32.6 (3.5)
22.9 (1.4)
18.8 (2.3)
1.9 (0.2)
2.0 (0.2)
2.6 (0.1)
1.9 (0.4)
29.9 (1.6)
30.8 (6.7)
238 (65)
109 (24)
19.5 (3.6)
21.9 (4.3)
2.3 (0.2)
2.1 (0.3)
5.8 (0.9)
4.5 (1.5)
826 (120)
472 (69)
216 (85)
145 (68)
1974 (507)
1099 (292)
2709 (185)
3358 (824)
4989 (556)
3710 (320)
557 (71)
508 (59)
1204 (111)
733 (150)
2116 (122)
1976 (259)
17.7 (2)
14.2 (1.1)
15.0 (1)
11.9 (1.5)

Values are mean (SEM). Abbreviations: EPA, eicosapentaenoic acid; DPA, Docosapentaenoic
acid; DHA, docosahexaenoic acid.
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5.7

Fatty acids

Fatty acid analysis began at myristic acid (14:0) and continued to docosahexaenoic acid (22:6n3). Finally, the omega-3 index was defined as the sum of 20:5n-3 (EPA) and 22:6n-3 (DHA)
adjusted by a regression equation (r = 0.97) to predict the omega-3 index in the RBC. Omega-3
fatty acid composition was expressed as a percent of total identified fatty acids (table 5.13). All
fatty acids are shown in table 5.13.

There were no significant differences between groups at baseline for any fatty acid (P>0.05) (table
5.13). There was an increase in EPA (20:5n-3) (P<0.05), DHA (22:6n-3) (P<0.01), and the omega3 index (P<0.01) within the fish oil group post supplementation (table 5.13, figure 5.3) There was
a difference in DHA (22:6n-3) (P<0.01), DPA (20:2n-6) (P<0.05) and the omega-3 index (P<0.01)
between control and fish oil post supplement (table 5.13, figure 5.3). Finally, there was a decrease
in eicosadienoic acid (20:2n-6) within the fish oil group (P<0.05) (table 5.13).
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Table 5.13. Fatty acid composition expressed as a percent of total identified fatty acids from a
whole blood, dry sample.
Control
Fatty Acid
14:0
16:0
16:1n-7t
16:1n-7
18:0
18:1t
18:1n-9
18:2n-6t
18:2n-6
20:0
18:3n-6
20:1n-9
18:3n-3
20:2n-6
22:0
20:3n-6
20:4n-6
24:0
20:5n-3
24:1n-9
22:4n-6
22:5n-6
22:5n-3
22:6n-3
O3I

Pre
1.09 (0.20)
23.80 (0.76)
0.20 (0.01)
1.48 (0.23)
11.11 (0.29)
0.61 (0.05)
22.92 (0.80)
0.24 (0.02)
18.65 (1.21)
0.21 (0.01)
0.32 (0.04)
0.31 (0.02)
0.43 (0.04)
0.21 (0.01)
0.45 (0.05)
1.48 (0.09)
8.70 (0.62)
0.61 (0.12)
1.04 (0.14)
0.65 (0.14)
0.90 (0.09)
0.16 (0.02)
1.31 (0.05)
3.12 (0.19)
6.06 (0.29)

Post
1.21 (0.18)
23.04 (0.77)
0.18 (0.01)
1.28 (0.22)
11.86 (0.31)
0.62 (0.05)
21.97 (0.85)
0.30 (0.02)
18.76 (1.41)
0.23 (0.02)
0.30 (0.04)
0.33 (0.04)
0.43 (0.03)
0.21 (0.01)
0.51 (0.05)
1.50 (0.10)
9.04 (0.63)
0.77 (0.08)
0.93 (0.05)
0.81 (0.09)
1.07 (0.10)
0.18 (0.02)
1.37 (0.05)
3.08 (0.16)
5.88 (0.18)

Fish Oil
Pre
1.04 (0.20)
22.29 (0.85)
0.14 (0.02)
1.45 (0.28)
11.64 (0.38)
0.48 (0.05)
21.15 (1.06)
0.24 (0.03)
20.83 (1.68)
0.24 (0.02)
0.25 (0.04)
0.39 (0.04)
0.65 (0.19)
0.26 (0.02)
0.42 (0.04)
1.52 (0.09)
9.13 (0.53)
0.58 (0.10)
0.96 (0.09)
0.66 (0.12)
1.01 (0.08)
0.18 (0.02)
1.34 (0.06)
3.16 (0.17)
6.01 (0.23)

Post
0.83 (0.11)
21.81 (0.67)
0.17 (0.02)
1.03 (0.19)
11.73 (0.36)
0.43 (0.05)
21.81 (0.85)
0.22 (0.02)
20.32 (1.31)
0.24 (0.02)
0.17 (0.02)
0.30 (0.04)
0.50 (0.06)
0.20 (0.01)*
0.51 (0.05)
1.36 (0.09)
8.61 (0.47)
0.74 (0.08)
1.38 (0.12)*
0.79 (0.08)
0.78 (0.06)
0.18 (0.01)
1.15 (0.05)#
4.75 (0.22)**†
8.31 (0.37)**†

Omega-3 index is equivalent to red blood cell EPA+DHA. *P<0.05 within groups, **P<0.01
within groups, †P<0.01 between groups, #P<0.05 between groups. Control (n=8), fish oil
(n=9). Values are mean (SEM). Abbreviations: O3I, omega-3 index.
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Figure 5.3. Whole blood EPA, DHA, and red blood cell equivalent omega-3 index for control
(n=8) and fish oil (n=9) groups, pre and post supplementation.
Fatty acid values expressed as a percentage of total identified fatty acids. *P<0.05, **P<0.01.
Abbreviations: EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
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The dose of EPA and DHA administered in the fish oil group was adjusted per unit of body mass
and then compared to changes in red blood cell EPA, DHA, EPA+DHA, and finally the omega-3
index. There was no significant relationship between adjusted EPA and DHA dose and any red
blood cell long-chain fatty acid (table 5.14).

Table 5.14. Bodyweight-adjusted capsule dose compared to change in long-chain fatty acids in
whole blood and omega-3 index in red blood cells.
Adjusted intake
EPA (mg/kg)
DHA (mg/kg)
EPA+DHA (mg/kg)
EPA+DHA (mg/kg)

Whole blood fatty acid change RBC EPA+DHA change
EPA
DHA EPA+DHA
Omega-3 index
0.00
0.05
0.02
0.02

P-value
0.99
0.57
0.72
0.72

Data from fish oil group (n=9). Values are reported as R2.
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5.8

Senior Fitness Assessment

Physical function data are shown in table 5.15. No significant differences were observed between
the groups at baseline or after supplementation for anthropometrics or physical function, including
walking speed tests (P>0.05).

Using normative self-paced walking speed data for age and gender (Bohannon and Williams
Andrews 2011), participants were ranked based on whether they met the normal speed at baseline
for their 20m usual walking speed assessment. There were 5 participants who did not meet the
normative walking speed. Omega-3 index and overnight mean heart rate were then assessed for
differences in those who did and did not meet the normative walking speed. There were no
significant differences in omega-3 index or heart rate in those who did and did not meet normative
walking speeds (table 5.16).
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Table 5.15. Physiological and senior fitness assessment data, before and after supplementation.
Control
Pre
Cardiovascular
SBP (mmHg)
DBP (mmHg)
Heart rate (bpm)
Physical Function
Left grip (kg)
Right grip (kg)
Left pinch (kg)
Right pinch (kg)
Sit to stand (reps)
Timed up and go (s)
Bicep Curl (reps)
Walking Speed
20m usual speed (m/s)
20m rapid speed (m/s)
400m speed (m/s)

129 (5)
74 (3)
71 (3)

Fish Oil
Post
128 (4)
79 (3)
73 (4)

Pre

Post

136 (3)
77 (2)
66 (3)

131 (3)
74 (3)
65 (3)

23.63 (3.66)
23.25 (3.89)
6.69 (0.83)
7.25 (0.90)
18.75 (2.12)
4.32 (0.27)
19.63 (1.87)

23.53 (2.94)
22.78 (3.04)
7.25 (0.94)
8.06 (1.33)
20.13 (1.75)
4.43 (0.34)
22.50 (2.80)

26.22 (3.45)
27.78 (3.67)
7.78 (0.78)
7.78 (0.85)
20.22 (1.99)
4.14 (0.26)
20.11 (1.76)

27.40 (2.97)
29.68 (3.84)
7.54 (0.62)
7.66 (0.57)
21.00 (2.37)
4.06 (0.19)
20.78 (2.06)

1.27 (0.05)
1.76 (0.09)
1.55 (0.06)

1.34 (0.07)
1.80 (0.09)
1.58 (0.07)

1.25 (0.04)
1.90 (0.08)
1.59 (0.05)

1.29 (0.04)
1.83 (0.09)
1.59 (0.06)

Control (n=8), fish oil (n=9). Values are mean (SEM). Abbreviations: SBP, systolic blood
pressure; DBP, diastolic blood pressure; reps, repetitions.

Table 5.16. Omega-3 index and overnight heart rate in those that did (n=5) and did not meet
(n=12) normative walking speed for age and gender.
Meet normative walk
criteria?
Yes
No

Omega-3 index
(%)
6.1 (0.01)
5.7 (0.04)

Mean overnight heart rate
(bpm)
61 (2)
62 (3)

Values are mean (SEM). Abbreviations: bpm, beats per minute.
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Physical activity data collected from the International Physical Activity Questionnaire (IPAQ) and
self-perceived physical and mental fatigue data collected from the Pittsburgh Fatigability Scale
(PFS) are shown in table 5.17. There were no significant differences in reported physical activity,
or reported physical or mental fatigue between groups at baseline or post-supplementation
(P>0.05).

The 400m walk test was broken down into the 10 individual laps and finally a mean for all 10 laps.
There was no difference in walking speed or absolute heart rate (figure 5.4). The resting tissue
saturation index (%) was not different at baseline between the groups (control: pre, 71.62±6.55;
fish oil: pre, 73.44±3.93), neither was the mean tissue saturation index (%) during the 400m walk
(control: 43.14±1.67; fish oil: 40.82±1.71). When the tissue saturation index was expressed as a
relative change there remained no difference (figure 5.4).

Table 5.17. Self-reported physical activity (IPAQ) and physical and mental fatigue (PFS).
Control
Pre
IPAQ
Walk MET-min
Moderate MET-min
Vigorous MET-min
Total MET-min
Sit min
PFS
Physical fatigue
Mental fatigue

Fish Oil
Post

1234 (302)
937 (247)
1406 (616)
3577 (639)
295 (36)

1070 (260)
1156 (250)
1149 (504)
3375 (575)
246 (63)

7.0 (2.2)
4.0 (1.6)

8.1 (2.2)
4.0 (1.4)

Pre

Post

1238 (149)
1073 (336)
1040 (570)
3351 (728)
343 (81)

965 (270)
1400 (449)
1040 (423)
3405 (557)
312 (68)

9.3 (2.7)
8.1 (2.8)

8.9 (2.3)
7.6 (2.9)

Control (n=7), fish oil (n=7). Values are mean (SEM). Abbreviations: IPAQ, International
Physical Activity Questionnaire; MET, metabolic equivalents of task; PFS, Pittsburgh
Fatigability Scale.
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Figure 5.4. Walking speed, heart rate, and tissue saturation index during the 400m walk test.
Control (n=8), fish oil (n=9). Abbreviations: bpm, beats per minute; TSI, tissue saturation index.
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Height was then added as a covariable for heart rate analysis during the 400m walk test as there
was an association between height and walking speed in this study and other studies (Bohannon
1997, Mikos, Yen et al. 2018). In addition, due to the probability of walking velocity change as
participants get going in the first lap and approach the end and have energy left to expend in the
final lap, these laps were discarded from estimates of steady state velocity and heart rate during
the 400m walk test. There was a decrease in mean heart rate within the fish oil group pre to post
during the 400m walk test (P<0.01), in addition to a difference between the control and fish oil
groups post supplementation (P<0.01) (figure 5.5).
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Figure 5.5. Heart rate collected before and after supplementation during the 400m walk test in
the control (n=8) and fish oil (n=9) group.
Mean heart rate during laps 2-9 (first and last lap excluded). Covariable; height. *P<0.01.
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Heart rate recovery following the 400m walk test was measured as the heart beat drop from peak
within the first and second minute of seated rest. There were no significant differences in heart
rate recovery between groups (P>0.05) (table 5.18).

Table 5.18. Heart rate recovery (heart beat drop) at 1 minute and 2 minutes following the 400m
walk test.
Control
1 min
2 min

Pre
31 (2)
41 (3)

Fish Oil
Post
31 (2)
40 (3)

Pre
34 (3)
46 (3)

Post
35 (3)
47 (2)

Control (n=8), fish oil (n=9). Values are mean (SEM).

5.9

Submaximal treadmill protocol

The submaximal treadmill protocol consisted of a 5 minute seated rest period prior to treadmill
walking, followed by 2 walking stages. Treadmill speed was increased during stage 1. Treadmill
incline was increased during stage 2. There were no significant differences in heart rate, net oxygen
consumption, oxygen cost of walking, tissue saturation index or rating of perceived exertion at rest
or during treadmill walking (P>0.05) (table 5.19).

Carbohydrate and fat oxidation rates, as well as the respiratory exchange ratio were not
significantly different at rest or during treadmill walking (P>0.05) (table 5.20).
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Table 5.19. Heart rate, oxygen consumption, oxygen cost of walking, tissue saturation index and
rating of perceived exertion data collected during the submaximal treadmill protocol.
Heart Rate (bpm)
Control
Resting
Stage 1
Stage 2

Resting
Stage 1
Stage 2

Pre
74 (2)
113 (5)
126 (7)

Fish Oil
Post
74 (3)
111 (6)
121 (8)

Pre
69 (3)
106 (4)
111 (5)

Post
65 (2)
102 (4)
110 (5)

Net oxygen consumption (mL/kg/min)
Control
Fish Oil
Pre
Post
Pre
Post
2.97 (0.28)
3.33 (0.43)
2.82 (0.27)
2.99 (0.26)
13.64 (1.85)
11.46 (0.97)
10.11 (1.10)
12.01 (1.08)
17.19 (1.58)
14.73 (1.82)
13.06 (0.58)
14.71 (0.95)
Oxygen cost of walking (mL/m)
Control

Stage 1
Stage 2

Stage 1
Stage 2

Pre
0.32 (0.04)
0.08 (0.01)

Fish Oil
Post
0.27 (0.03)
0.07 (0.01)

Pre
0.26 (0.04)
0.06 (0.01)

Post
0.31 (0.03)
0.07 (0.01)

Relative change in tissue saturation index (%)
Control
Fish Oil
Pre
Post
Pre
Post
-44.97 (6.16)
-37.46 (4.94)
-40.97 (3.27)
-38.00 (3.93)
-51.96 (4.92)
-41.60 (5.10)
-49.10 (4.25)
-44.03 (5.03)
Rating of perceived exertion
Control

Stage 1
Stage 2

Pre
9 (0.6)
12 (0.9)

Fish Oil
Post
10 (0.8)
12 (0.9)

Pre
10 (0.8)
11 (1.0)

Post
10 (0.9)
11 (1.6)

Resting and stage one heart rate and stage one tissue saturation index; control (n=8), fish oil
(n=9). Resting oxygen consumption and stage one net oxygen consumption and oxygen cost of
walking; control (n=7), fish oil (n=9). Resting and stage two heart rate and stage one tissue
saturation index; control (n=7), fish oil (n=7). Stage two net oxygen consumption and oxygen
cost of walking; control (n=6), fish oil (n=7). Abbreviations: bpm, beats per minute. Resting
oxygen consumption expressed at gross oxygen consumption.
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Table 5.20. Carbohydrate oxidation rate, fat oxidation rate and respiratory exchange ratio at rest
and during stage one and stage two of treadmill walking.
Carbohydrate use (g/min)
Control
Resting
Stage 1
Stage 2

Pre
0.15 (0.04)
0.95 (0.23)
1.42 (0.32)

Fish Oil
Post
0.31 (0.13)
0.80 (0.15)
1.17 (0.28)

Pre
0.21 (0.08)
0.82 (0.12)
1.07 (0.15)

Post
0.16 (0.03)
0.94 (0.13)
1.16 (0.17)

Fat use (g/min)
Control

Fish Oil

Resting
Stage 1
Stage 2

Pre
0.04 (0.01)
0.21 (0.03)
0.16 (0.04)

Post
0.01 (0.03)
0.21 (0.03)
0.18 (0.04)

Pre
0.02 (0.02)
0.14 (0.02)
0.15 (0.02)

Post
0.04 (0.01)
0.15 (0.03)
0.16 (0.02)

Resting
Stage 1
Stage 2

Respiratory exchange ratio (V̇CO2/V̇O2)
Control
Fish Oil
Pre
Post
Pre
Post
0.86 (0.03)
0.95 (0.07)
0.92 (0.05)
0.86 (0.02)
0.88 (0.02)
0.87 (0.01)
0.90 (0.01)
0.91 (0.01)
0.92 (0.03)
0.90 (0.03)
0.91 (0.01)
0.91 (0.01)

Resting and stage one; control (n=7), fish oil (n=9). Stage two; control (n=6), fish oil (n=7).
Abbreviations: V̇CO2/V̇O2, ratio between volume of carbon dioxide released and volume of
oxygen consumed.

71

Heart rate recovery was then assessed for 10 minutes following exercise cessation with the
participant laying supine in a dark room using a heart rate decay formula (t1/2) which examined the
half time for heart rate to drop back to resting. There was no difference detected between groups
for half time recovery (table 5.21). Total heart beat drop at the end of the 10-minute supine period
was not significantly different between groups post-supplementation (table 5.21).

Table 5.21. Heart rate recovery following the treadmill walking protocol.
Control
Minimum HR (bpm)
Peak HR (bpm)
t1/2 (s)
Total beat drop

Pre
58 (2)
127 (6)
131 (16)
68 (6)

Fish Oil
Post
58 (2)
121 (6)
127 (16)
63 (6)

Pre
55 (2)
115 (3)
125 (18)
60 (3)

Post
51 (2)
112 (3)
109 (19)
61 (3)

Control (n=8), fish oil (n=9). Abbreviations: HR, heart rate; bpm, beats per minute; t1/2, time to
half.
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5.10

Ambulatory 24-hour heart rate monitoring

All participants completed the 24-hour heart rate monitoring. The mean (SEM) sample duration
for the control group was 403 (35) minutes pre supplement and 494 (30) minutes post supplement.
The mean (SEM) sample duration for the fish oil group was 507 (23) minutes pre supplement and
509 (19) minutes post supplement. There were no significant differences in sample duration
between groups (P>0.05). There were no significant differences (P>0.05) for mean overnight heart
rate or time, non-linear or frequency heart rate variability domains at baseline and following the
supplementation period (table 5.22). There was a small, non-significant reduction (P=0.28) in heart

H e a rt ra te c h a n g e (b e a ts )

rate change for the fish oil group (-2.2 beats) compared to control (-0.8 beats) (figure 5.6).
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Figure 5.6. Heart rate change collected via a cardiac monitor during overnight sleep in control
(n=8) and fish oil (n=9) groups. P=0.28.
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Table 5.22. Overnight heart rate and heart rate variability parameters.
Control
Mean heart rate (bpm)
Night-day heart rate ratio
SDNN (ms)
RMSSD (ms)
SD1 (ms)
SD2 (ms)
SD2/SD1
Power HF-band
Power LF-band
Power VLF-band
Power total
LF/HF

Pre
63 (2)
0.90 (0.04)
63.17 (5.07)
20.36 (2.82)
14.40 (2.00)
88.03 (7.34)
6.75 (0.87)
162.42 (51.43)
320.40 (60.68)
2065.30 (837.49)
2548.10 (867.08)
2.83 (0.58)

Post
62 (2)
0.86 (0.04)
74.12 (9.73)
20.35 (3.30)
14.39 (2.33)
103.71 (13.69)
7.88 (1.03)
165.51 (56.07)
293.73 (81.42)
1454.60 (235.17)
1913.80 (337.35)
2.92 (0.60)

Fish Oil
Pre
60 (2)
0.91 (0.04)
89.34 (8.25)
27.66 (5.94)
19.56 (4.20)
124.47 (11.39)
7.97 (1.04)
247.50 (87.08)
529.67 (136.96)
2077.10 (336.39)
2854.20 (518.51)
3.34 (0.63)

Post
57 (2)
0.87 (0.05)
78.76 (5.26)
31.17 (6.53)
22.04 (4.62)
108.64 (6.99)
6.48 (1.01)
322.04 (114.68)
612.41 (151.69)
1854.60 (289.13)
2789.10 (500.60)
3.16 (0.72)

Control (n=8), fish oil (n=9). Values are mean (SEM). Abbreviations: bpm, beats per minute;
SDNN, standard deviation of normal to normal intervals; RMSSD, root mean square of the
successive differences; SD1, standard deviation of points perpendicular to the axis of line-ofidentity; SD2, standard deviation of points along the axis of line-of-identity; SD1/SD2, ratio of
SD1 to SD2; HF-band, high frequency band; LF-band, low frequency band; VLF-band, very low
frequency band; LF/HF, ratio of LF to HF bands.
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During the 10 minute period of overnight sleep where heart rate was the lowest recorded, the heart
rate difference pre to post in the fish oil group was significantly different (P<0.05) to the control
group (figure 5.7). No significant differences (P>0.05) were seen for time, non-linear or frequency

H e a rt ra te c h a n g e (b e a ts )

heart rate variability domains during the lowest 10 minute period (table 5.23).
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Figure 5.7. Heart rate change during the lowest ten minute heart rate period overnight.
Control (n=8), fish oil (n=9). *P<0.05
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Table 5.23. Heart rate and heart rate variability parameters collected during the lowest ten
minute heart rate period overnight.
Control
Mean heart rate (bpm)
Night-day heart rate ratio
SDNN (ms)
RMSSD (ms)
SD1 (ms)
SD2 (ms)
SD2/SD1
Power HF-band
Power LF-band
Power VLF-band
Power total
LF/HF

Pre
58 (2)
0.83 (0.03)
36.58 (8.40)
20.31 (3.83)
14.36 (2.71)
49.36 (11.78)
3.53 (0.45)
187.68 (72.57)
317.36 (118.25)
1052.20 (656.36)
1557.30 (781.18)
1.97 (0.36)

Post
58 (2)
0.81 (0.03)
48.89 (6.28)
22.11 (4.68)
15.63 (3.31)
66.94 (8.72)
5.01 (0.85)
203.54 (94.29)
397.79 (129.29)
1247.50 (393.83)
1848.80 (533.94)
3.33 (0.89)

Fish Oil
Pre
55 (2)
0.85 (0.03)
37.79 (4.73)
26.70 (4.58)
18.88 (3.24)
49.09 (6.75)
3.17 (0.61)
262.84 (89.25)
368.79 (74.38)
748.82 (227.02)
1380.50 (268.46)
3.02 (0.65)

Post
52 (2)
0.79 (0.04)
45.92 (6.97)
29.12 (5.70)
20.59 (4.03)
60.48 (9.88)
3.57 (0.84)
260.92 (96.20)
380.73 (108.08)
962.82 (262.66)
1604.50 (388.38)
2.69 (1.01)

Control (n=8), fish oil (n=9). Values are mean (SEM). Abbreviations: bpm, beats per minute;
SDNN, standard deviation of normal to normal intervals; RMSSD, root mean square of the
successive differences; SD1, standard deviation of points perpendicular to the axis of line-ofidentity; SD2, standard deviation of points along the axis of line-of-identity; SD1/SD2, ratio of
SD1 to SD2; HF-band, high frequency band; LF-band, low frequency band; VLF-band, very low
frequency band; LF/HF, ratio of LF to HF bands.
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6.

Discussion

In healthy older adults, a low dose of DHA-rich fish oil increased the omega-3 index, indicative
of lower cardiovascular disease risk, and delivering physiological change, in particular to heart
rate, that may be of benefit in an aging population.

6.1

Aged physiology

Participants in the current study would be classified as highly fit and high functioning older adults.
This is based on their physical function measures compared to normative data based on age in a
group of healthy older adults (Rikli and Jones 1999). During the sit to stand assessment participants
achieved a total of 7 and 5 repetitions more than normative values for males and females,
respectively (Rikli and Jones 1999). As it relates to the 30s arm curl assessment, participants
achieved an additional 5 (male) and 2 (female) compared to normative values (Rikli and Jones
1999). Participants were also 22% (male) and 26% (female) faster during the timed up and go
assessment compared with normative values (Rikli and Jones 1999). Rikli et al., (2013) determined
the functional fitness values required to maintain physical independence during older life (Rikli
and Jones 2013). Even with these higher reference values, participants in the current study
exceeded the sit to stand values by 7 repetitions (male) and 4 repetitions (female), arm curl values
by 5 repetitions (male) and 1 repetition (female), and were faster during the timed up and go by
25% (male) and 20% female). Taken together, this can be interpreted as participants in the current
study being at the top end of physical function based on age and have not experienced a large
decline in physical function with age, even when compared with healthy older adults.
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In the current study, participants had a preferred walking speed at baseline of 1.26m/s, surpassing
speeds associated with higher mortality risk (<0.8m/s) (Stanaway, Gnjidic et al. 2011, Studenski,
Perera et al. 2011), lower extremity limitation and death (<1.0m/s) (Cesari, Kritchevsky et al.
2005), in addition to exceeding the normative criteria for age of 1.19m/s in a group of healthy
adults (Bohannon and Williams Andrews 2011). Walking speeds over 1.2m/s suggest life
expectancy well above the average and it is here where the participants in the current study fit
(Studenski, Perera et al. 2011).

Older adults who have a slower walking speed display higher fatigue over 24 hours and overall
perform less physical activity as the day progresses (Schrack, Simonsick et al. 2010, Schrack,
Zipunnikov et al. 2014). Even in a high functioning group of older adults, this physiological
process was evident in the current study. Walking speed collected during the 20m and 400m walk
tests was inversely associated with the oxygen cost of walking on the treadmill, that is, the slower
walkers also had the highest oxygen cost of walking on the treadmill. This supports Wert et al.,
(2013) that, when measured separately, found an inverse association between walking speed and
energy cost of walking, as in the current study (Wert, Brach et al. 2013).

As it relates to oxygen cost of walking at varying treadmill speeds and gradients, the current study
found that participants had a higher relative oxygen cost of walking at the slower treadmill speeds,
however as the treadmill speed increased and they approached their usual walking speed there was
a decrease in the relative oxygen cost of walking. This is in line with the literature, in that there is
a U-shaped relationship between the oxygen cost of walking and walking speed, whereby oxygen
cost of walking is higher at very low and very high walking speeds. The optimal speed or
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economical speed is the walking speed which minimises the energy cost of walking (Abe, Fukuoka
et al. 2015). As in the current study, Schrack et al., (2016) also found an inverse association
between walking speeds and energy cost of walking in older adults (Schrack, Zipunnikov et al.
2016).

6.2

Long-chain omega-3 polyunsaturated fatty acids: intake and supplementation
6.2.1

Determination of omega-3 status

The current study used the omega-3 index as the primary outcome describing the omega-3 status
of participants. In the current study, neither the whole blood LC n-3 PUFA nor the omega-3 index
aligned well with either of the dietary assessments of omega-3 intake. This questions the validity
of these short term measures for establishing habitual intake for individuals and demonstrates the
importance of using direct measures of incorporation, such as the omega-3 index, to link to
physiological or clinical effect. This was further highlighted by the large variations in fat intake
reported in the 3-day food record.

The original development and validation of the PUFA FFQ in estimating blood levels of LC n-3
PUFA was performed in a relatively young group of adults with a maximum age of 58 years old
(Sullivan, Williams et al. 2006, Sullivan, Brown et al. 2008). The PUFA FFQ used in the current
study was the electronically administered version which has been validated in a relatively small
sample of adults, including older adults (Swierk, Williams et al. 2011). Although older adults aged
59-79 years (n=12) were included during the development and validation of the electronically
administered PUFA FFQ, a separate analysis was not performed on that age group and therefore
the inclusion of all ages may limit the applicability to older adults alone. The PUFA FFQ is
reported to capture dietary intake of previous 3 months which is an important consideration when
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investigating foods which are consumed infrequently, such as fish. Despite Swierk et al., (2011)
reporting that the PUFA FFQ adequately estimates blood levels of LC n-3 PUFA across a wide
age range, the current study did not reflect these findings.

The lack of agreement between the 3-day food record and blood levels of LC n-3 PUFA is not
surprising. Fish consumption does not often occur on a daily basis and the possibility for
underreporting fish intake is higher. Nonetheless, dietary data from the 3-day food record was not
collected for the purpose of estimating blood levels of LC n-3 PUFA, but rather to establish no
change in nutrient or energy intake throughout the study or between groups. Due to the lack of
agreement between self-reported dietary measures and objective blood markers, it highlights the
importance of measuring circulating blood biomarkers such as the omega-3 index before and after
supplementation to objectively evaluate the effect of LC n-3 PUFA on outcome measures. In
addition, the use of the omega-3 index, which is the content of EPA + DHA in RBC membranes,
expressed as a percent of total fatty acids (Harris and Von Schacky 2004), is more representative
of chronic fish intake compared with plasma (Harris, Varvel et al. 2013). Considerations when
designing omega-3 clinical trials have been addressed (Rice, Bernasconi et al. 2016). These
considerations include an adequate dose of long-chain omega-3 fatty acids to see an effect in
primary outcome measures, an appropriate study population with low baseline omega-3 status, and
measurement of omega-3 status at baseline and during treatment to ensure low omega-3 levels at
baseline and to assess compliance. In the present study, the omega-3 index (Harris and Von
Schacky 2004) was used to screen out participants with a high omega-3 index at baseline and
appropriately match participants into the control and fish oil groups to prevent one group from
having a significantly different omega-3 status at baseline.
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6.2.2

Dose and composition of supplemental omega-3 fatty acids

The current study showed that low dose DHA-rich fish oil supplemented for 16 weeks significantly
increased the omega-3 status from baseline, elevating the omega-3 index over the desired 8%
which has been suggested for optimal cardio protection (Harris and Von Schacky 2004). The dose
used in the current study is in line with the current Australian Dietary Guidelines of approximately
2 fish meals per week (National Health and Medical Research Council 2013). Dietary fish oil
incorporation of LC n-3 PUFA into skeletal and cardiac muscle has been examined in animal
models (Ayre and Hulbert 1996, Pepe and McLennan 1996, Peoples and McLennan 2010, Peoples
and McLennan 2014). There is preferential incorporation of DHA into skeletal muscle when
supplemented with DHA-rich fish oil (Peoples and McLennan 2010) and this occurs even when
an EPA-rich fish oil source is used (Pepe and McLennan 1996). In rats, DHA is preferentially
incorporated into heart and skeletal muscle with little change in EPA levels (Owen, PeterPrzyborowska et al. 2004). Incorporation of LC n-3 PUFA into skeletal and cardiac muscle is also
evident at lower doses, whereby DHA in rats is preferentially incorporated into type 2 muscle
fibers (Henry, Peoples et al. 2015), and myocardial membranes (Slee, McLennan et al. 2010)
following low dietary doses of DHA-rich fish oil. Changes in erythrocytes show a similar
relationship with higher DHA incorporation in dogs (Stoeckel, Nielsen et al. 2011). The findings
from animal models have been further evaluated in humans. As in the animal models, LC n-3
PUFA successfully incorporate into human cardiac (Metcalf, James et al. 2007) and human skeletal
muscle membranes (Andersson, Nalsen et al. 2002, Haugaard, Madsbad et al. 2006, McGlory,
Galloway et al. 2014).
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The finding of an elevated omega-3 index in the current study was achieved through low dose
DHA-rich fish oil supplementation. The measurement of erythrocyte fatty acids are reflective of
EPA+DHA content in human cardiac tissue (Harris, Sands et al. 2004, Metcalf, Cleland et al. 2010)
and human skeletal muscle tissue (Andersson, Nalsen et al. 2002). In the current study, the increase
in the omega-3 index was primarily driven by DHA, rather than EPA. This supports work done in
rodents, showing that DHA incorporates to a greater extent than EPA within muscle tissues (Slee,
McLennan et al. 2010, Henry, Peoples et al. 2015). Milte et al., (2008) supplemented a DHA-rich
fish oil in middle aged adults at DHA doses ranging from low (520mg/d) to high (1560mg/d). In
agreement with the current study, it was found that all doses caused a significant increase in
erythrocyte EPA+DHA content, however it was DHA that drove the increase in erythrocyte
EPA+DHA at all doses, rather than EPA (Milte, Coates et al. 2008). This is supported further by
the findings of Theobald et al., (2004) who supplemented middle aged adults with low dose DHA
which caused a significant increase in erythrocyte DHA, whereas EPA remained unchanged
(Theobald, Chowienczyk et al. 2004). In addition to Allaire et al., (2017) which established that
when EPA and DHA are supplemented individually, it is DHA which caused the greater increase
in the omega-3 index compared with EPA in middle aged adults (Allaire, Harris et al. 2017). Flock
et al., (2013) found a similar result whereby DHA increases more than EPA within erythrocytes,
however in this study an EPA-rich fish oil capsule was used, highlighting the preferential
incorporation of DHA over EPA irrespective of a higher supplemental dose of EPA (Flock, SkulasRay et al. 2013).

Other studies in older adults have predominantly used high doses of fish oil, with EPA-rich fish
oil capsules (Smith, Atherton et al. 2011, Rodacki, Rodacki et al. 2012, Hutchins-Wiese,
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Kleppinger et al. 2013, Krzymińska-Siemaszko, Czepulis et al. 2015, Monahan, Feehan et al. 2015,
Smith, Julliand et al. 2015, Clark, Monahan et al. 2016, Da Boit, Sibson et al. 2017, Alfaddagh,
Elajami et al. 2018, Clark, Monahan et al. 2018). Not only does the high dose make it difficult to
reproduce through dietary sources, but the higher proportion of EPA to DHA in most studies are
also not representative of fatty acid profiles of fresh fish, which are often higher in DHA rather
than EPA (Soltan and Gibson 2008, Mozaffarian and Wu 2011). The current study differed from
other studies in older adults in that participants were supplemented with a low dose of DHA-rich
fish oil, which could be reproduced by dietary intake of approximately 2 fatty fish meals per week,
yet it still established a significant increase in the omega-3 index, driven by DHA. To date,
increases in erythrocyte EPA+DHA following low dose DHA-rich fish oil supplementation,
reflective of fresh fish (Soltan and Gibson 2008, Mozaffarian and Wu 2011), have been established
in healthy young (Macartney, Hingley et al. 2014, Hingley, Macartney et al. 2017) and middleaged adults (Theobald, Chowienczyk et al. 2004, Milte, Coates et al. 2008). The current study adds
to these findings by establishing the effect of a low dose of DHA-rich fish oil in elevating the
omega-3 index in older adults.

6.3

Effect of fish oil on cardiovascular outcomes at rest and exercise

Fish oil consumption successfully reduced heart rate during fast paced walking over 400m, and
this occurred without a change in physical work. This indicates that submaximal heart rate can be
affected in older adults, as in healthy, well trained young adults and with the use of much lower
fish oil intakes than were previously used (Peoples, McLennan et al. 2008, Buckley, Burgess et al.
2009).
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As it relates to older adults, Logan et al., (2015) found that high dose EPA-rich fish oil
supplementation for 12 weeks reduced submaximal heart rate by 2 beats during low intensity
cycling in older females. In contrast, the dose of fish oil used by Logan et al., (2015) was higher
in EPA compared to DHA and approximately 4 times greater than what was used in the current
study. The heart rate reduction in the current study of 7 beats is higher to what was reported by
Logan et al., (2015), however the exercise intensity used by Logan et al., (2015) was very low
(40% of heart rate reserve) and may not have been sufficient to see a greater effect of the heart rate
lowering caused by fish oil supplementation.

Macartney et al., (2014) supplemented healthy males with the same low dose of DHA-rich fish oil
used in the current study. Following 8 weeks of supplementation, participants achieved a
submaximal heart rate reduction of 4.5 beats which is in line with what was found in the current
study. The current study is the first study to establish that a low dose of DHA-rich fish oil
successfully reduces submaximal exercise heart rate in a group of healthy, active older adults.

In contrast to the heart rate lowering effects found in the 400m walk test, a lowered heart rate was
not observed during the treadmill walking assessment, where heart rate reached approximately
75% of age-predicted maximum, compared to the 85% of age-predicted maximum in the 400m
walk. There are several possibilities that may have contributed to this outcome. It was noted that
the influence of walking instability on the treadmill and anxiety during treadmill speed changes
caused heart rate to fluctuate to a greater extent than during over ground walking, often causing
elevations in heart rate not explainable by work load, despite participants being familiarized with
the treadmill protocol. This was confirmed by the participants perceived rating of exertion
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corresponding to ‘light’ activity during the most difficult stage of the treadmill walk. This finding
of an elevated heart rate, not explained by work rate, in older adults during treadmill walking has
been documented in other studies (Swerts, Mostert et al. 1990, Greig, Butler et al. 1993). When
comparing to corridor walking, Greig et al., (1993) found that treadmill walking, at equal speed,
resulted in an elevated heart rate in the elderly. The use of a mouthpiece, which was used on
treadmill but not over ground walking also affected heart rate. The current study did not use
equivalent walking speeds between treadmill walking and over ground walking assessments,
however a mouth piece was used to collect oxygen consumption on the treadmill. There are a
number of potential reasons which may explain the unexpected heart rate response to treadmill
walking in the elderly, including fear of falling, altered stride length and altered cadence (Peeters
and Mets 1996, Wass, Taylor et al. 2005, Marsh, Katula et al. 2006). Taken together, the
adjustments which occur during treadmill walking seem to reflect instability and lack of balance
which influence heart rate responses to treadmill walking. Therefore, the 400m walking test
appears to more accurately reflect free living conditions in older adults and it is here where fish
oil was found to lower heart rate.

The current study showed that in the context of highly active, healthy older adults, the low dose of
DHA-rich fish oil also reduced minimum overnight heart rate. The effects of fish oil feeding in
reducing intrinsic heart rate is evident in human cardiac transplant patients (Harris, Gonzales et al.
2006), and in animal models (Pepe and McLennan 2002, Dhein, Michaelis et al. 2005,
Abdukeyum, Owen et al. 2008, Verkerk, den Ruijter et al. 2009) where vagal tone is not present.
Verkerk et al., (2009) established that the prolonged cardiac cycle length found in rabbits fed a
diet enriched with fish oil was a result of a reduction in pacemaker current density in isolated sino-
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atrial node cells. These intrinsic effects of fish oil on heart rate are at least in part due to the ability
of polyunsaturated fatty acids in modulating myocardial calcium handling and preventing
spontaneous calcium release (Negretti, Perez et al. 2000, Leifert, Dorian et al. 2001,
Sankaranarayanan and Venetucci 2012). The current study supports the hypothesis of a direct
effect of fish oil in lowering intrinsic heart rate because overnight heart rate variability, a measure
of autonomic function, was unchanged as a result of fish oil supplementation, suggesting that the
reduction in minimum overnight heart rate occurred in the absence of either increased
parasympathetic nervous system activity, or decreased sympathetic nervous system activity.
Additionally, the nocturnal dip that occurs during overnight sleep is also an indicator of autonomic
function and is related to sympathetic over activity. DHA-rich fish oil did not have an effect on
the ratio between night-day heart rate in the current study. Taken together, this implies that low
dose DHA-rich fish oil had a direct effect on intrinsic heart rate, as all measures relating to
autonomic function were not influenced by fish oil supplementation.

An elevated resting heart rate is strongly associated with mortality and cardiovascular disease risk
(Palatini, Casiglia et al. 1999, Kristal-Boneh, Silber et al. 2000, Cooney, Vartiainen et al. 2010,
Saxena, Minton et al. 2013, Custodis, Roggenbuck et al. 2016, Tadic, Cuspidi et al. 2018). Recent
evidence suggests that night-time heart rate has stronger prognostic value in mortality and
cardiovascular disease risk than resting heart rate collected during the day (Ben-Dov, Kark et al.
2007, Hansen, Thijs et al. 2008, Johansen, Olsen et al. 2013). This is likely due to the variations
in heart rate from external stimuli (Mancia, Bertinieri et al. 1983, Watanabe, Reece et al. 2007,
Smolders, de Kort et al. 2012).
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Despite the importance and clinical usefulness of overnight heart rate, little work has been done
surrounding fish oil’s effects on overnight heart rate lowering. There is evidence in children that
fish oil lowers overnight heart rate (Buchhorn, Willaschek et al. 2017), however the current study
is the first to provide evidence that a low dose of fish oil lowers intrinsic heart rate during overnight
sleep in healthy, active older adults.

Up to this point in time the primary method for selective heart rate lowering has been through
pharmacological intervention (Bruguera Cortada and Varela 2009, Tardif 2009, Rosano, Vitale et
al. 2010), however the reduction in heart rate, both at rest and exercise, often decreases heart rate
reserve and exercise capacity during exercise (Van Baak 1988, Van Bortel and Van Baak 1992,
Vanhees, Defoor et al. 2000). There is strong evidence to support the heart rate lowering effects
of fish oil (Mozaffarian, Geelen et al. 2005), however in contrast to the heart rate lowering
achieved with pharmacological intervention, the lowering of heart rate achieved with fish oil does
not reduce cardiovascular function or exercise capacity and under some conditions can even serve
to improve it (Peoples, McLennan et al. 2008, Macartney, Hingley et al. 2014, Hingley, Macartney
et al. 2017).

The association of reduced heart rate with an elevated omega-3 index is novel. The omega-3 index
has predominantly been investigated for its role in overall cardiovascular disease risk (Harris
2008), whereas in the current study it was found that elevating the omega-3 index above 8%
resulted in a reduction in heart rate at rest and during exercise. Notably, elevated heart rate is a
significant contributor to risk of mortality (Palatini, Casiglia et al. 1999, Seccareccia, Pannozzo et
al. 2001, Jouven, Empana et al. 2005, Zhang, Shen et al. 2016). A recent meta-analysis found a
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reduction in resting heart rate of approximately 2.5 beats with fish oil supplementation (Hidayat,
Yang et al. 2017), and the results from the current study are in line with these findings. The
significance of a 3-4 beat per minute reduction in heart rate as seen in the current study on a lower
sudden death risk appears to be approximately 7-10% on the basis of Jouven et al., (2005) and a
10% decrease in cardiovascular death and hospital admission for worsening heart failure (Bohm,
Swedberg et al. 2010). Not only is a lower resting heart rate advantageous for reducing risk of allcause (Seccareccia, Pannozzo et al. 2001, Jouven, Empana et al. 2005, Zhang, Shen et al. 2016)
and cause-specific mortality (Palatini, Casiglia et al. 1999, Fox, Borer et al. 2007), but more
recently the significance of a consistently low resting heart rate over time has been highlighted as
an independent risk factor for all-cause mortality (Wang, Li et al. 2017). As the consumption of
fish and fish oil supplementation incorporates LC n-3 PUFA, in particular DHA, into myocardial
membranes there is opportunity for long term physiological remodeling and thus a consistent heart
rate lowering effect. Future research should aim to determine if this is also part of the cardiac
protective effects when fish is consumed in the diet.

6.4

Effect of fish oil on physical function and strength measures

In the current study, fish oil supplementation did not change physical function or strength
measures, however a small positive correlation was found between pinch grip strength and the
omega-3 index at baseline within the entire cohort. There is a lack of consistency between findings
of increased strength measures from fish oil supplementation. It seems that EPA-rich fish oil
primarily serves to augment muscle strength increases, only when combined with a resistance
training program (Rodacki, Rodacki et al. 2012, Da Boit, Sibson et al. 2017), whereas the current
study did not combine DHA-rich fish oil supplementation with an exercise intervention, but rather
recruited physically active older adults who did not change their exercise regimes. Smith et al.,
88

(2015) found a significant increase in muscle strength after high dose EPA-rich fish oil
supplementation without a combined resistance training program, however the participants in the
control group decreased their muscle strength to a similar extent as the fish oil group increased
muscle strength. Smith et al., placed no control over physical activity or dietary behaviors
throughout the intervention and this may explain their unexpected finding. Other studies have
found no effect of fish oil on muscle strength in older adults with decreased muscle mass
(Krzymińska-Siemaszko, Czepulis et al. 2015) or who met pre-frail or frail criteria (HutchinsWiese, Kleppinger et al. 2013).

When assessed for walking speed, participants in the current study far exceeded values associated
with mortality risk (Abellan van Kan, Rolland et al. 2009, Stanaway, Gnjidic et al. 2011), lower
extremity limitation, hospitalisation and death (Cesari, Kritchevsky et al. 2005), as well as the
normative values for age (Bohannon and Williams Andrews 2011). Fish oil supplementation did
not alter walking speed in the current study. Older adults who have a slower walking speed display
higher fatigue over 24 hours and overall perform less physical activity as the day progresses
(Vestergaard, Nayfield et al. 2009, Schrack, Zipunnikov et al. 2014). Large variability between
individuals exists as to the extent of muscle mass and physical function loss with age. Modifiable
physical activity and nutrition behaviors largely explain the variability in the rate of muscle mass
and physical function loss (Witard, McGlory et al. 2016). The participants in the current study
were highly active, healthy older adults. Participants reported on average a total of 79 minutes per
day of moderate intensity physical activity in the International Physical Activity Questionnaire
which is more than double the Australian Government recommendation of 30 minutes on most,
preferably all, days. In addition, participants reported very low mental and physical fatigue in the
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Pittsburgh Fatigability Scale. The Pittsburgh Fatigability Scale is designed to measure perceived
fatiguability in older adults across a range of day to day tasks and ranges from 0-50, whereby a
higher score represents high fatiguability. Participants reported mean scores under 10 in both
physical and mental fatigue, indicating a very low fatiguing cohort. Taken together, the high
reported physical activity, and low reported fatigability, in addition to the high walking speed of
the participants, it is not surprising that further improvements were not seen in walking speed or
physical function measures. The effects fish oil on walking speed appear to only be evident in slow
walkers with walking speeds under approximately 1.0 m/s. Data from the Three-City-Bordeaux
study did show an association between high plasma concentrations of LC n-3 PUFA and higher
walking speed in 982 adults aged 65 years and over (Frison, Boirie et al. 2015), however walking
speed in this group was low, at below 1.0 m/s. Conversely, in participants with a walking speed
over 1.0 m/s, Fougere et al., (2018) found no difference in walking speed of older adults at baseline
between participants in the lowest quartile of omega-3 status compared to those in the upper three
quartiles. Interventions involving omega-3 fatty acids have found similar results. In a group of
older aged female participants who met pre-frail or frail criteria and displayed walking speed
around 1.0m/s, fish oil was able to significantly increase walking speed, however the increase was
small (0.03m/s) (Hutchins-Wiese, Kleppinger et al. 2013). There is a consistent lack of effect of
high dose EPA-rich fish oil supplementation on walking speed in randomised control trials where
older adults walk faster than 1.0m/s (Rodacki, Rodacki et al. 2012, Da Boit, Sibson et al. 2017).

6.5

Effect of fish oil on oxygen cost of exercise

During the treadmill walking protocol, the current study found no effect of fish oil supplementation
on oxygen consumption or oxygen cost of walking. There is limited research around the role of
omega-3 fatty acids in oxygen modulation and oxygen cost of walking in older adults. In contrast
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to the finding of no change in the current study, Logan et al., (2015) reported an increase in oxygen
consumption from high dose fish oil supplementation in older adults. This is surprising due to the
role of omega-3 fatty acids in oxygen modulation within muscle, more specifically improving the
efficiency of oxygen use, reflected in reduced whole body oxygen consumption in well trained
cyclists (Peoples, McLennan et al. 2008). The ability of LC n-3 PUFA to incorporate into cardiac
tissue is also shared with skeletal muscle tissue (Andersson, Nalsen et al. 2002, Owen, PeterPrzyborowska et al. 2004, McGlory, Galloway et al. 2014), and therefore the observed effects of
a more efficient use of oxygen as a result of LC n-3 PUFA incorporation within the heart are also
present within skeletal muscle as shown in animal models (Peoples and McLennan 2010, Peoples
and McLennan 2014, Henry, Peoples et al. 2015). A lower skeletal muscle oxygen consumption
was required for tension development in rats fed a fish oil diet (Peoples and McLennan 2014). The
findings of a lower oxygen consumption from fish oil feeding in animal models has been
investigated in humans, whereby a lower oxygen consumption is achieved with fish oil
supplementation in aerobically trained (Peoples, McLennan et al. 2008, Hingley, Macartney et al.
2017) and untrained males (Kawabata, Neya et al. 2014). The increase in oxygen consumption
reported by Logan et al., (2015) comes without an increase in workload, therefore suggesting a
less efficient use of oxygen, which is not consistent with other animal or human evidence (Peoples,
McLennan et al. 2008, Peoples and McLennan 2010, Kawabata, Neya et al. 2014, Peoples and
McLennan 2014, Henry, Peoples et al. 2015, Hingley, Macartney et al. 2017). In fact, in other
trials performed from the same lab as Logan et al., (2015) they have found either variable effects
(Gerling, Whitfield et al. 2014) or no effect (Jannas-Vela, Roke et al. 2017) of fish oil
supplementation on oxygen consumption in healthy recreationally active young (<25 years) males.
Nonetheless, the finding of no change in oxygen consumption or oxygen cost of walking in the
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current study may be related to the aforementioned walking instability and anxiety during treadmill
speed changes which made it difficult to represent an accurate heart rate response. Oxygen
consumption is heavily influenced by heart rate during exercise (Bernard, Gavarry et al. 1997) and
therefore due to heart rate being influenced by factors not relating only to work load during the
treadmill protocol it may not provide an accurate representation of oxygen cost of walking or
oxygen consumption for the given workloads. Perhaps a portable metabolic analyser which can be
used during self-paced walking would provide a representation of oxygen consumption which is
more reflective of free living conditions.

The effect of fish oil supplementation on lowering oxygen consumption during exercise is best
evident under high external workloads causing a high physiological challenge (Peoples, McLennan
et al. 2008, Kawabata, Neya et al. 2014, Hingley, Macartney et al. 2017). Participants in the current
study were only exercising at approximately 75% of their age predicted maximum during the
treadmill protocol and walking at a speed of approximately 65% of their over ground walking
speed. Moreover, their responses across the range of physical assessments suggests they may have
a higher than average maximum heart rate for age and therefore a greater physical activity reserve.
The decline in physical function, muscle mass, and strength with age is highly variable. It is now
known that habitual exercise training has the ability to strongly limit the age-associated decline in
VO2max, peak strength and muscle mass (Wroblewski, Amati et al. 2011), as found in a recent
meta-analysis comparing these parameters in master’s athletes (McKendry, Breen et al. 2018). It
was found that master endurance athletes have comparable VO2max values to healthy young
controls and above the values achieved in healthy, but less active older adults. It was also found
that master strength/power athletes were stronger than the older age controls (McKendry, Breen et
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al. 2018). Clearly, there is a notable gap in the rate of decline between individuals who are
physically capable and those who are not.
6.6

Summary

Using a randomised placebo-controlled design, the aim of this study was to investigate the ability
of low dose DHA-rich fish oil to modify cardiovascular function and physical performance, on the
basis of an elevated omega-3 index. Careful screening included blood analysis of omega-3 status
to ensure participants were not consuming fish or fish oil at a level that might obscure the effects
of a low dose supplement, in addition to representing the median Australian LC n-3 PUFA intake
or below. This resulted in a group of fit, healthy and active older adults, where the oxygen cost of
exercise is still inherently linked to their walking speed. The strengths of this study included the
randomised placebo-controlled design which had strict inclusion criteria to ensure participants
were highly active to allow for repeatable physical performance at each visit and to minimize the
chance of day to day performance variation as often seen in older adults.

6.7

Limitations

The participants in the current study were highly active older adults who displayed physical fitness,
often in the highest functional categories for age. This allowed participants to successfully
complete all the physical assessments required in the study, however it also meant that further
improvement was less likely. Furthermore, due to the high physical performance of participants in
the current study, the physical function assessments, such as timed up and go, sit to stand and the
400m walk test did not provide a strong physiological stress, whereas these tests are more
demanding in older adults with lower physical function.
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The current study included multiple visits with tightly controlled in-laboratory physiological tests,
in addition to a range of functional and at-home assessments. This increased the participant burden
which, in turn, made it difficult to achieve larger participant numbers. Potential participants were
often limited by transport and having to travel to the University for several visits. The small sample
size is a limitation of the current study. It is likely that measures such as heart rate recovery which
approached significance, may have achieved significance if participant numbers were higher.

Despite fish oil supplementation successfully elevating the omega-3 status, participants still had a
baseline omega-3 index of 6% which is not within the undesirable range for overall cardiovascular
disease risk.

6.8

Recommendations for future studies

Future studies should investigate the role of low dose DHA-rich fish oil in modifying the oxygen
cost of exercise and improving physical function, in particular walking speed, either (i) in a more
fatigable cohort, where it is evident that participants have experienced notable age-associated
declines in physical function, or (ii) within a highly active group of older adults as in the current
study, however using more sensitive measures to capture muscle fatigue differences, such as using
ultrasound images to detect muscle architecture (sonomyography) which has successfully been
used to study muscle fatigue (Shi, Zheng et al. 2007). Using physical function measures which are
more physiologically demanding, such as isokinetic and isometric maximum voluntary contraction
(MVC) in a highly active and high functioning cohort may allow for further improvement in
outcome measures as a result of supplementation. If a more fatigable cohort is used, future studies
may benefit from placing a greater focus on functional assessments such as corridor walking,
which can be completed at local recreation facility where older adults regularly visit, such as lawn
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bowl clubs and tennis centres. In addition, recruiting participants with a lower omega-3 status at
baseline may allow for further improvement in outcome measures.
6.9

Conclusion

There were three fundamental outcomes of the current study;
First, confirming hypothesis one, a DHA-rich fish oil supplement (2g/day) did significantly modify
the whole blood and specifically the erythrocyte membranes and reflected LC n-3 PUFA DHA in
the diet. As a consequence, the omega-3 index was elevated into the low risk category for
cardiovascular disease in this group of active older adults.

Second, confirming hypothesis two, an increased omega-3 index had demonstrable effects on
cardiovascular function at rest and during exercise, namely a reduction in heart rate during
overnight sleep and also during the 400m walking assessment. The extent of heart rate reduction
is in line with what has been reported in population studies and meta-analysis. In fact, these
reductions were observed independent of either increased parasympathetic nervous system activity
or decreased sympathetic nervous system activity as demonstrated by unaltered heart rate
variability and nocturnal dip. Therefore, this suggests a direct action of DHA-rich fish oil on the
heart to lower intrinsic beat rate.

Third, DHA-rich fish oil supplementation did not modify the oxygen cost of exercise during
treadmill walking, or walking speed during usual or rapid walking tests. Additionally, physical
function measures, including grip strength, were not improved after supplementation. Therefore,
in a group of healthy older adults, hypothesis three was rejected for this population of older adults.
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